<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="jimd12697" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Inherit Metab Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Inherit Metab Dis</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JIMD</journal-id><journal-title-group><journal-title>Journal of Inherited Metabolic Disease</journal-title></journal-title-group><issn pub-type="ppub">0141-8955</issn><issn pub-type="epub">1573-2665</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11108624</article-id><article-id pub-id-type="pmcid-ver">PMC11108624.1</article-id><article-id pub-id-type="pmcaid">11108624</article-id><article-id pub-id-type="pmcaiid">11108624</article-id><article-id pub-id-type="pmid">38221762</article-id><article-id pub-id-type="doi">10.1002/jimd.12697</article-id><article-id pub-id-type="publisher-id">JIMD12697</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Gene Therapy</subject></subj-group></article-categories><title-group><article-title>Gene therapy for neurotransmitter&#8208;related disorders</article-title><alt-title alt-title-type="left-running-head">Chu et al.</alt-title></title-group><contrib-group><contrib id="jimd12697-cr-0001" contrib-type="author"><name name-style="western"><surname>Chu</surname><given-names initials="WS">Wing Sum</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3517-2200</contrib-id><xref rid="jimd12697-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jimd12697-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jimd12697-cr-0002" contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="J">Joanne</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7946-9965</contrib-id><xref rid="jimd12697-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jimd12697-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jimd12697-cr-0003" contrib-type="author"><name name-style="western"><surname>Waddington</surname><given-names initials="SN">Simon N.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4970-4730</contrib-id><xref rid="jimd12697-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jimd12697-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jimd12697-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Kurian</surname><given-names initials="MA">Manju A.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3529-5075</contrib-id><xref rid="jimd12697-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="jimd12697-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>manju.kurian@ucl.ac.uk</email></address></contrib></contrib-group><aff id="jimd12697-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Gene Transfer Technology Group, EGA Institute for Women's Health</named-content>
<institution>University College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="jimd12697-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Genetic Therapy Accelerator Centre, Queen Square Institute of Neurology</named-content>
<institution>University College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="jimd12697-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Wits/SAMRC Antiviral Gene Therapy Research Unit, Faculty of Health Sciences</named-content>
<institution>University of the Witwatersrand</institution>
<city>Johannesburg</city>
<country country="ZA">South Africa</country>
</aff><aff id="jimd12697-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, Great Ormond Street Institute of Child Health</named-content>
<institution>University College London</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><aff id="jimd12697-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>Great Ormond Street Hospital for Children</institution>
<city>London</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Manju A. Kurian, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, Great Ormond Street Institute of Child Health, University College London, 20 Guildford Street, London WC1N 1DZ, UK.<break/>
Email: <email>manju.kurian@ucl.ac.uk</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>1</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2024</year></pub-date><volume>47</volume><issue seq="140">1</issue><issue-id pub-id-type="pmc-issue-id">462864</issue-id><issue-id pub-id-type="doi">10.1002/jimd.v47.1</issue-id><issue-title content-type="special-issue-title">Mission possible: gene therapy for inherited metabolic diseases</issue-title><fpage>176</fpage><lpage>191</lpage><history><date date-type="rev-recd"><day>14</day><month>11</month><year>2023</year></date><date date-type="received"><day>06</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>11</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>21</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>22</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-22 18:25:22.913"><day>22</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Authors. <italic toggle="yes">Journal of Inherited Metabolic Disease</italic> published by John Wiley &amp; Sons Ltd on behalf of SSIEM.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JIMD-47-176.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JIMD-47-176.pdf"/><abstract><title>Abstract</title><p>Inborn errors of neurotransmitter (NT) metabolism are a group of rare, heterogenous diseases with predominant neurological features, such as movement disorders, autonomic dysfunction, and developmental delay. Clinical overlap with other disorders has led to delayed diagnosis and treatment, and some conditions are refractory to oral pharmacotherapies. Gene therapies have been developed and translated to clinics for paediatric inborn errors of metabolism, with 38 interventional clinical trials ongoing to date. Furthermore, efforts in restoring dopamine synthesis and neurotransmission through viral gene therapy have been developed for Parkinson's disease. Along with the recent European Medicines Agency (EMA)&#160;and Medicines and Healthcare Products Regulatory Agency (MHRA) approval of an AAV2 gene supplementation therapy for AADC deficiency, promising efficacy and safety profiles can be achieved in this group of diseases. In this review, we present preclinical and clinical advances to address NT&#8208;related diseases, and summarise potential challenges that require careful considerations for NT gene therapy studies.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jimd12697-kwd-0001">AADC deficiency</kwd><kwd id="jimd12697-kwd-0002">DTDS</kwd><kwd id="jimd12697-kwd-0003">Gene therapy</kwd><kwd id="jimd12697-kwd-0004">inborn errors of neurotransmission</kwd><kwd id="jimd12697-kwd-0005">neurotransmitter disease</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Great Ormond Street Hospital Charity
</institution><institution-id institution-id-type="doi">10.13039/501100001279</institution-id></institution-wrap></funding-source><award-id>V1284</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>LifeArc
</institution><institution-id institution-id-type="doi">10.13039/100012357</institution-id></institution-wrap></funding-source><award-id>P2023&#8208;0002</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Medical Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100000265</institution-id></institution-wrap></funding-source><award-id>MR/K02342X/1</award-id><award-id>MR/R015325/1</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>National Institute for Health and Care Research
</institution><institution-id institution-id-type="doi">10.13039/501100000272</institution-id></institution-wrap></funding-source><award-id>NIHR&#8208;RP&#8208;2016&#8208;07&#8208;019</award-id></award-group><award-group id="funding-0005"><funding-source><institution-wrap><institution>Rosetrees Trust
</institution><institution-id institution-id-type="doi">10.13039/501100000833</institution-id></institution-wrap></funding-source><award-id>M576</award-id></award-group><award-group id="funding-0006"><funding-source><institution-wrap><institution>Sir Jules Thorn Charitable Trust
</institution><institution-id institution-id-type="doi">10.13039/501100000282</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0007"><funding-source><institution-wrap><institution>Wellcome Trust
</institution><institution-id institution-id-type="doi">10.13039/100010269</institution-id></institution-wrap></funding-source><award-id>WT098524MA</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><page-count count="16"/><word-count count="12918"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.3 mode:remove_FC converted:21.05.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jimd12697-cit-9001"><string-name name-style="western"><surname>Chu</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Waddington</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>. <article-title>Gene therapy for neurotransmitter&#8208;related disorders</article-title>. <source>J Inherit Metab Dis</source>. <year>2024</year>;<volume>47</volume>(<issue>1</issue>):<fpage>176</fpage>&#8208;<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12697</pub-id><pub-id pub-id-type="pmid">38221762</pub-id><pub-id pub-id-type="pmcid">PMC11108624</pub-id></mixed-citation>
</p><fn-group id="jimd12697-ntgp-0001"><fn id="jimd12697-note-0001"><p>
<bold>Communicating Editor</bold>: Georg Hoffmann</p></fn></fn-group></notes></front><body id="jimd12697-body-0001"><sec id="jimd12697-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Neurotransmitters (NT) are a diverse group of chemical messengers, including the mainly inhibitory aminoacidergic (&#947;&#8208;aminobutyric acid [GABA] and glycine), excitatory aminoacidergic (aspartate and glutamate), and monoaminergic (adrenaline, noradrenaline, dopamine [DA] and serotonin [5&#8208;HT]) systems.<xref rid="jimd12697-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> NT are generally synthesised, stored, and released from pre&#8208;synaptic neurons, diffuse across the synaptic cleft to bind to post&#8208;synaptic receptors, and finally transported or enzymatically degraded for termination of neurotransmission.<xref rid="jimd12697-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Inborn errors of NT metabolism (IEM&#8208;NT) are a rare group of conditions due to defects in NT synthesis, metabolism or reuptake.<xref rid="jimd12697-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jimd12697-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> For the purpose of this review, we focus on IEM&#8208;NT as defined by the International Working Group on Neurotransmitter&#8208;related Disorders.<xref rid="jimd12697-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> However, many other disorders can also impair NT homeostasis with abnormal cerebrospinal fluid (CSF) NT profiles, including mitochondrial diseases, channelopathies and disorders of sphingolipid and cholesterol synthesis.<xref rid="jimd12697-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</p><p>The majority of IEM&#8208;NT affects monoamine synthesis, metabolism, and reuptake, namely DA and 5&#8208;HT (Figure&#160;<xref rid="jimd12697-fig-0001" ref-type="fig">1</xref>). DA is synthesised from <sc>l</sc>&#8208;tyrosine in two steps: to levodopa (<sc>l</sc>&#8208;DOPA), by rate&#8208;limiting tyrosine hydroxylase (TH) with essential co&#8208;factor tetrahydrobiopterin (BH<sub>4</sub>); then by aromatic <sc>l</sc>&#8208;amino acid decarboxylase (AADC) and co&#8208;factor pyridoxal 5&#8208;phosphate (PLP; active form of vitamin B<sub>6</sub>).<xref rid="jimd12697-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> DA can also be converted into noradrenaline by dopamine &#946;&#8208;hydroxylase. Monoamines are then packaged into vesicles by vesicular monoamine transporter&#8208;2 (VMAT2), a neurotransmitter transporter (NTT), for subsequent Ca<sup>2+</sup>&#8208;mediated docking and fusion to release into the synapse. Dopamine transporter (DAT), a plasma membrane NTT, reuptakes DA from synaptic cleft to spatiotemporally regulate synaptic DA neurotransmission.<xref rid="jimd12697-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> One key monoamine degradation pathway is oxidative deamination by monoamine oxidase A.<xref rid="jimd12697-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Pathogenic variants have been identified in genes encoding enzymes and transporter proteins mentioned above.<xref rid="jimd12697-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jimd12697-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Due to shared metabolic pathways between DA and 5&#8208;HT, 5&#8208;HT levels can be affected in pterin defects, AADC deficiency (AADCD) and VMAT2 deficiency.</p><fig position="float" fig-type="FIGURE" id="jimd12697-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Selected pre&#8208;synaptic neurotransmitter metabolic pathway with gene therapies in clinic and under development. Proteins known to be involved in IEM&#8208;NT are coloured yellow; those with preclinical and clinical gene therapy investigations are in bold, and type of strategies are indicated by respective icons. Dashed lines indicate intermediate metabolic steps not shown; drawings not to scale. Created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://biorender.com" ext-link-type="uri">BioRender.com</ext-link>. 5&#8208;HIAA, 5&#8208;hydroxyindoleacetic acid; 5&#8208;HT, serotonin; 5&#8208;HTP, 5&#8208;hydroxytryptophan; AADC, aromatic <sc>l</sc>&#8208;amino acid decarboxylase; AAV, adeno&#8208;associated virus; ASO, antisense oligonucleotide; BH4, tetrahydrobiopterin; COMT, catechol&#8208;<italic toggle="yes">O</italic> methyl transferase; DA, dopamine; DAT, dopamine transporter; DBH, dopamine &#946;&#8208;hydroxylase; NHTP, dihydroneopterin triphosphate; DOPAL, 3,4&#8208;dihydroxyphenylacetaldehyde; GABA, &#947;&#8208;aminobutyric acid; GABA&#8208;T, GABA transaminase; GAD, glutamic acid decarboxylase; GAT, GABA transporter; GHB, gamma&#8208;hydroxybutyric acid; GTP, guanosine&#8208;5&#8242;&#8208;triphosphate; HVA, homovanillic acid; l&#8208;DOPA, levodopa; MAO, monoamine oxidase; OCT3/PMAT, organic cation transporter 3/plasma membrane monoamine transporter; PLP, pyridoxal phosphate; PTP, 6&#8208;pyruvoyltetrahydropterin; PTPS, 6&#8208;pyruvoyltetrahydropterin synthase; RV, retroviral; SSA, succinic semialdehyde; SSADH, succinic semialdehyde dehydrogenase; SERT, serotonin transporter; TCA, tricarboxylic acid; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; VIAAT, vesicular inhibitory amino acid transporter; VMAT2, vesicular monoamine transporter 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JIMD-47-176-g001.jpg"/></fig><p>Patients with IEM&#8208;NT present with a number of common clinical features, though often with variable age of onset, severity and treatment response.<xref rid="jimd12697-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jimd12697-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> For monoamine NT disorders, the spectrum includes neonatal hypotonia, movement disorders such as dystonia, parkinsonism, eye movement disorders including oculogyric crisis (OGC), autonomic dysfunction, and developmental delay.<xref rid="jimd12697-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jimd12697-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>, <xref rid="jimd12697-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Brain magnetic resonance imaging (MRI) abnormalities are also observed but are non&#8208;specific, including reduced brain volume, delayed myelination and watershed area changes.<xref rid="jimd12697-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jimd12697-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> Previously, a timely and accurate diagnosis was a challenge due to the need for specialist diagnostic investigations, for instance, CSF NT analysis. Clinical symptoms may also mimic a range of neurological disorders (such as hypoxic ischaemic encephalopathy and cerebral palsy), resulting in misdiagnosis and diagnostic delay.<xref rid="jimd12697-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jimd12697-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> The increasing availability of exome and genome sequencing techniques has accelerated diagnosis for many rare diseases patients and has changed how children with IEM&#8208;NTs are now identified; genetic testing now often precedes and sometimes avoids the need for CSF NT analysis.<xref rid="jimd12697-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>Depending on the underlying disorder, treatment approaches include use of co&#8208;factors (e.g., sapropterin dihydrochloride, pyridoxine) and/or NT precursors (e.g., <sc>l</sc>&#8208;DOPA, 5&#8208;hydroxytryptophan [5&#8208;HTP]) supplementation.<xref rid="jimd12697-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jimd12697-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jimd12697-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Treatment responses vary between IEM&#8208;NT, with some being curative, such as low dose <sc>l</sc>&#8208;DOPA with dopa decarboxylase (DDC) inhibitor in autosomal dominant GCH1 deficiency, some with variable responses like in AADCD and TH deficiency (THD), and others being medically refractory, such as dopamine transporter deficiency syndrome (DTDS).<xref rid="jimd12697-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jimd12697-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jimd12697-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jimd12697-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Moreover, in IEM&#8208;NT that are treatable, including some BH<sub>4</sub> disorders, symptom resolution and quality of life are often associated with early treatment initiation.<xref rid="jimd12697-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> As such, novel therapeutic approaches like gene therapy are promising to address underlying gene defects in drug&#8208;resistant forms of IEM&#8208;NT.</p><p>Gene therapy aims to deliver genetic materials by viral or non&#8208;viral carriers, known as vectors, to address disease&#8208;specific cellular dysfunctions.<xref rid="jimd12697-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Current European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA)&#8208;approved in vivo neurological gene therapy, namely Zolgensma&#174; (onasemnogene abeparvovec) for Spinal Muscular Atrophy (SMA) and Upstaza&#8482; (eladocagene exuparvovec) for AADCD, utilise viral vectors called adeno&#8208;associated virus (AAV). In this review, we will mainly focus on AAV&#8208;based NT gene therapies.</p><p>Wild&#8208;type (WT) AAV is a replication&#8208;deficient parvovirus with a 4.7 kilobases (kb) single&#8208;stranded (ss) DNA genome; recombinant AAV vectors (rAAV) retain only the inverted terminal repeats, which involve in vector packaging, transduction and transgene expression.<xref rid="jimd12697-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jimd12697-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref> Self&#8208;complementary AAV (scAAV) bypasses the rate&#8208;limiting second strand synthesis, thereby achieving earlier and higher level of transgene expression<xref rid="jimd12697-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>; but induces higher immune responses than ssAAV in mice.<xref rid="jimd12697-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jimd12697-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Different combinations of AAV capsid, regulatory elements (RE) such as promoters and delivery route are adopted depending on desired expression profile.<xref rid="jimd12697-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> Generally, capsid serotype determines tissue tropism due to recognition of specific cell surface receptors, followed by particle internalisation, endosomal escape, uncoating and subsequent transgene transcription.<xref rid="jimd12697-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jimd12697-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Capsid engineering, by rational design, ancestral sequence reconstruction, or directed evolution by DNA shuffling, could further enhance transduction, specificity, and CNS&#8208;specific axonal retrograde and/or anterograde transport.<xref rid="jimd12697-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jimd12697-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> Many novel capsids are being tested in clinical trials, for example, AAV&#8208;LK03 (liver&#8208;tropic,<xref rid="jimd12697-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> for haemophilia A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03003533">NCT03003533</ext-link>)<xref rid="jimd12697-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>), and Anc80 (liver, muscle and retina&#8208;targetting,<xref rid="jimd12697-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> for Wilson disease [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04537377">NCT04537377</ext-link>]). The inclusion of <italic toggle="yes">cis</italic>&#8208;acting RE can further define transgene specificity and expression level.<xref rid="jimd12697-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jimd12697-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> Most clinical trial gene therapy constructs employ ubiquitous promoters such as cytomegalovirus (CMV) and hybrid CMV immediate&#8208;early enhancer/chicken &#946;&#8208;actin promoter (CAG).<xref rid="jimd12697-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> This has added benefits if transgene products can be secreted for cross&#8208;correction, for instance, in lysosomal storage diseases.<xref rid="jimd12697-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> Tissue&#8208;specific promoters could potentially limit off&#8208;target expression and related toxicities<xref rid="jimd12697-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>; inducible,<xref rid="jimd12697-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> and activity&#8208;dependent,<xref rid="jimd12697-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> promoters are in development but have not reached clinical application. Recent rodent and non&#8208;human primates (NHP) studies indicate capsid&#8208;promoters interactions may impact cell&#8208;type selectivity as well.<xref rid="jimd12697-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="jimd12697-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> Other RE, including intron, polyadenylation (polyA) signal, and woodchuck hepatitis virus post&#8208;transcriptional regulatory element (WPRE), increase transgene expression level by promoting mRNA stability and/or nuclear export,<xref rid="jimd12697-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> whereas inserting binding sites for tissue or cell&#8208;specific microRNAs at 3&#8242; end can regulate transgene transcript levels,<xref rid="jimd12697-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> and prevented transgene overexpression in mice.<xref rid="jimd12697-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Delivery route is another important consideration for the desired vector biodistribution profile and safety. For CNS diseases, direct parenchymal delivery is relatively invasive and can result in focal or broad transduction; the latter is achievable by retrograde/anterograde transport due to extensive connectivity of regions such as putamen and thalamus.<xref rid="jimd12697-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> Alternatively, intracerebroventricular (ICV), intra&#8208;cisterna magna, and intrathecal (IT) injections utilise CSF flow for distribution, resulting in spinal and brain transduction with some peripheral &#8216;leakage&#8217;.<xref rid="jimd12697-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Intravenous (IV) delivery is feasible for some serotypes (e.g., AAV9, rh8, rh10) that can cross the blood&#8211;brain barrier; however, concerns about large doses, systemic genotoxicity and immunogenicity may prompt the use of alternative routes.<xref rid="jimd12697-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> It is also possible to undertake dual delivery, such as intrathalamic (ITH) and IT delivery is undertaken in GM2 gangliosidosis patients.<xref rid="jimd12697-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</p><p>One of the first NT&#8208;related gene therapies was for Parkinson's disease (PD), which provided important clinical evidence relevant to the development of gene therapy for IEM&#8208;NT. PD is a neurodegenerative disorder with no disease&#8208;modifying therapy currently available; symptomatic improvement from <sc>l</sc>&#8208;DOPA declines as PD progresses.<xref rid="jimd12697-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref> Different gene therapy strategies have been reviewed in detail elsewhere.<xref rid="jimd12697-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="jimd12697-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> Of particular interest, intraparenchymal delivery of DA (AADC, with or without TH and guanosine triphosphate cyclohydrolase 1 [GTPCH, rate&#8208;limiting of BH<sub>4</sub> synthesis]),<xref rid="jimd12697-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="jimd12697-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="jimd12697-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="jimd12697-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="jimd12697-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="jimd12697-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="jimd12697-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="jimd12697-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> and GABA (glutamic acid decarboxylase 65 and 67 [converts glutamate to GABA]),<xref rid="jimd12697-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="jimd12697-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="jimd12697-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref> synthesis enzymes were generally well&#8208;tolerated in clinical trials. Common adverse events in DA trials included treatment&#8208;related dyskinesia and surgery&#8208;related events. In a Phase 2 rAAV2&#8208;AADC trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03562494">NCT03562494</ext-link>), which used a higher infusion volume of 1800&#8201;&#956;L/putamen,<xref rid="jimd12697-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> T2 MRI abnormalities were observed and thus placed on clinical hold, and the sponsor partnership was terminated in 2021.<xref rid="jimd12697-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>
</p><p>With the clinical precedents of NT gene therapies developed for PD, insights into vector design, dosage, delivery methods, safety, tolerability, and transduction of neural pathways are valuable for developing gene therapies for IEM&#8208;NT in the clinic.<xref rid="jimd12697-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> The recent EMA and MHRA approvals of Upstaza&#8482; for AADCD and recommendation by the National Institute for Health and Care Excellence (HST26) have further paved the way for the development and translation of these disease&#8208;modifying therapies. Here, we summarise preclinical and clinical gene therapy studies for IEM&#8208;NT (Figure&#160;<xref rid="jimd12697-fig-0002" ref-type="fig">2</xref>) and discuss the potential future challenges in clinical translation.</p><fig position="float" fig-type="FIGURE" id="jimd12697-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Summary of clinical and preclinical advanced therapeutics for IEM&#8208;NT. 3&#8242;&#8208;UTR, 3&#8242;&#8208;untranslated region; AADCD, aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency; AAV, adeno&#8208;associated virus; ASO, antisense oligonucleotide; CMV, cytomegalovirus enhancer/promoter; DTDS, dopamine transporter deficiency syndrome; hAADC, human aromatic <sc>l</sc>&#8208;amino acid decarboxylase; hBG, human &#946;&#8208;globin; hBG2/3, human &#946;&#8208;globin partial intron 2/partial exon 3; hGHpA, human growth hormone polyadenylation signal; ICV, intracerebroventricular; IP, intraperitoneal; IT, intrathecal; IV, intravenous; N.D., not disclosed; PTPSD, pyruvoyltetrahydropterin synthase deficiency; RE, regulatory elements; RO, retro&#8208;orbital; RV, retroviral; SLC6A1, SLC6A1&#8208;related disorder (GABA transporter 1&#8208;related myotonic&#8208;astatic epilepsy); SN, substantia nigra; SNpc, substantia nigra pars compacta; SSADHD, succinic semialdehyde dehydrogenase deficiency; SV40pA, simian virus 40 early polyadenylation signal; vg, vector genomes; VTA, ventral tegmental area.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JIMD-47-176-g002.jpg"/></fig></sec><sec id="jimd12697-sec-0002"><label>2</label><title>GENE THERAPY FOR MONOAMINE NT DISORDERS</title><sec id="jimd12697-sec-0003"><label>2.1</label><title>AADC deficiency</title><p>AADCD (OMIM #608643) is a rare neurodevelopment disorder characterised by impaired DA and 5&#8208;HT synthesis due to biallelic mutations in the <italic toggle="yes">DDC</italic> (7p12.2) gene. Noradrenaline and adrenaline synthesis are also affected as they are downstream of DA; therefore, typical CSF markers include low DA, 5&#8208;HT, and noradrenaline metabolites, namely homovanillic acid (HVA), 5&#8208;hydroxyindoleacetic acid (5&#8208;HIAA) and 3&#8208;methoxy&#8208;4&#8208;hydroxyphenylglycol, along with high precursors <sc>l</sc>&#8208;DOPA and 5&#8208;HTP levels.<xref rid="jimd12697-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> A total of 120 patients have been published to date; 80% of cases are classified as severe, whereby patients typically present in the early months of life with hypotonia, OGC and developmental delay.<xref rid="jimd12697-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jimd12697-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> Autonomic dysfunction, such as&#160;excessive sweating and sleep disturbances, movement disorders, for example dystonia, and cerebral atrophy on brain MRI are also observed.<xref rid="jimd12697-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jimd12697-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="jimd12697-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> A higher prevalence in Taiwan is attributed to a founder variant c.714+4A&gt;T (IVS6+4A&gt;T), and homozygous patients manifest severe phenotypes, with severe motor impairment, weight stagnation and increased risk of premature death.<xref rid="jimd12697-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> Existing drug treatments, including DA agonists, monoamine oxidase inhibitors, vitamin B<sub>6</sub> and tonal agents such as benzodiazepines have limited benefits, and adverse effects are common.<xref rid="jimd12697-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>
</p><p>rAAV2 gene supplementation therapies targeting the putamen or midbrain have been trialled in AADCD patients. Upstaza&#8482;, approved by EMA and MHRA for severe AADCD in 18&#8208;month&#8208;old and above, is delivered as bilateral intraputaminal infusion (3&#8201;&#956;L/min, 80&#8201;&#956;L/site, 2 sites/hemisphere) at a total dose of 1.8&#8201;&#215;&#8201;10<sup>11</sup>vg.<xref rid="jimd12697-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> The construct contains AADC cDNA, CMV promoter, human &#946;&#8208;globin partial intron 2/partial exon 3, and simian virus 40 (SV40) polyA. A putaminal target was chosen due to its accessibility, striatal DA deficiency, connectivity in the cortico&#8208;basal ganglia network, and safety profiles from PD AADC trials.<xref rid="jimd12697-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> The compassionate use,<xref rid="jimd12697-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> Phase 1/2<xref rid="jimd12697-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref> and Phase 2b<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> trial treated a total of 21 patients (age range, 1.7&#8211;8.5&#8201;years) at 1.8&#8201;&#215;&#8201;10<sup>11</sup>vg, demonstrating continuous improvement in primary endpoints of gross and fine motor development (Peabody Developmental Motor Scales&#8211;Second Edition [PDMS&#8208;2]), significantly improved motor performance (Alberta Infant Motor Scale [AIMS]), cognitive function, language skills and AADC activity in putamen, as measured by PET <sup>18</sup>F&#8208;DOPA scans, up to 5&#8201;years post&#8208;treatment.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Milestone attainments, such as head control and sitting unassisted, were progressive, with 44% and 20% at 1&#8201;year and 75% and 67% at 5&#8201;years, respectively.<xref rid="jimd12697-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref> Reduced OGC frequency, increased CSF HVA (but not 5&#8208;HIAA), and improvement in weight gain, autonomic (sweating) and serotonergic (mood) symptoms were also reported 1&#8208;year post&#8208;treatment.<xref rid="jimd12697-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="jimd12697-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> No significant difference in PDMS&#8208;2 was achieved with higher dosage at 2.4&#8201;&#215;&#8201;10<sup>11</sup>vg in the Phase 2b study; rather, earlier treatment was significantly correlated to higher PDMS&#8208;2 scores and improvement in white matter microstructure on MRI.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> Three patients that are able to walk without assistance post&#8208;treatment were also treated early, by 4.2&#8201;years old.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Adverse events include surgical complications, pyrexia, and transient orofacial and limb dyskinesia, possibly due to early DA receptor hypersensitivity. Dyskinesia onset within 3&#8201;months of treatment, was relieved by risperidone and resolved by 10&#8201;months; severity and duration correlated with age of patients rather than dosage.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Lately, motor and non&#8208;motor improvements 1&#8208;year post&#8208;treatment were reported in two older patients (treated when &gt;10&#8201;years old) with severe AADCD, with improved putaminal <sup>18</sup>F&#8208;DOPA uptake compared to baseline.<xref rid="jimd12697-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</p><p>Similar results were shown in a Japanese Phase 1/2 rAAV2 study also using CMV promoter, showing significant putaminal AADC activity detected by PET, improved motor functions (AIMS), and reduced OGC duration up to 2&#8201;years post&#8208;gene therapy in severe AADCD patients.<xref rid="jimd12697-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> The gene therapy was administered at a higher concentration (i.e., lower infusion volume of 50&#8201;&#956;L/site, with a similar total dose of 2&#8201;&#215;&#8201;10<sup>11</sup>vg). Variable responses in CSF HVA levels and cognition were seen; transient orofacial dyskinesia and choreic movements occurred in all six patients, peaking at 2&#8201;months and diminishing by 6&#8201;months.<xref rid="jimd12697-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Further analysis showed PET tyrosine tracer uptake was significantly increased in the putamen and substantia nigra (SN) post&#8208;gene therapy, and associated with gross motor improvement via prefrontal cortico&#8208;putaminal network restoration.<xref rid="jimd12697-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref> Treatment of two patients with moderate AADCD, at 4 and 12&#8201;years of age, respectively, led to improvements in AIMS score, but improvement in the development quotient score was only seen in the earlier&#8208;treated patient.<xref rid="jimd12697-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref>
</p><p>Unlike in PD, midbrain structures in AADCD are not known to degenerate.<xref rid="jimd12697-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> Therefore, another approach is to directly deliver rAAV2&#8208;AADC to the midbrain, specifically to the SNpc and ventral tegmental area (VTA) DA neurons, to address DA deficiency in nigrostriatal and other dopaminergic pathways.<xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> Also driven by a CMV promoter, a Phase 1 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02852213">NCT02852213</ext-link>) study of seven patients (aged 4&#8211;9&#8201;years old) were treated at 1.3 or 4.2&#8201;&#215;&#8201;10<sup>11</sup>vg total dose by bilateral MRI&#8208;guided convection&#8208;enhanced delivery (50&#8201;&#956;L in SNpc and 30&#8201;&#956;L in VTA/hemisphere). Eighty percent coverage of both areas was obtained; <sup>18</sup>F&#8208;DOPA PET scan showed increased AADC activity in both the midbrain and striatum at 3 and 24&#8201;months, likely due to anterograde axonal transport of vector and AADC protein. Notably, complete and sustained resolution of OGC occurred within 9&#8211;33&#8201;days for 5 subjects; 6 (86%) gained head control and 4 (57%) could sit independently by 12&#8201;months. All five patients followed up till 18&#8201;months achieved clinically meaningful improvement in motor score (Gross Motor Function Measure; GMFM&#8208;88), reduction in irritability and insomnia. Similar to the trials reported above, post&#8208;treatment improvement in CSF HVA (but not 5&#8208;HIAA), and transient dyskinesia in all patients 3&#8211;4&#8201;weeks after treatment were observed. Ongoing dose&#8208;escalation study evaluated a larger volume (up to 300&#8201;&#956;L, 1 infusion/hemisphere, in between SNpc and VTA) and dose up to 1.5&#8201;&#215;&#8201;10<sup>12</sup>vg, and with a patient age range spanning from 4&#8208; to 27&#8208;year&#8208;old.<xref rid="jimd12697-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref>, <xref rid="jimd12697-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref>
</p><p>Recently, an early Phase 1 trial delivering AAV9&#8208;AADC (VGN&#8208;R09b) to bilateral putamen was initiated in China (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05765981">NCT05765981</ext-link>).<xref rid="jimd12697-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> The trial is recruiting children between 2 and 8&#8201;years with homozygous or compound heterozygous IVS6+4A&gt;T missense and baseline motor development &lt;3&#8201;months. Outcome measures are adverse events and motor development at 1&#8201;year. Dosage and construct design are not available.</p><p>Finally, since the founder variant c.714+4A&gt;T results in aberrant splicing and produces a premature stop codon from a pseudoexonic +38 cryptic splice site,<xref rid="jimd12697-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref> an antisense oligonucleotide (ASO) strategy was tested in vitro to restore normal mRNA splicing.<xref rid="jimd12697-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> ASO binds to target mRNA via Watson&#8208;Crick base pairing, and modulate pre&#8208;mRNA splicing via steric hindrance for the recruitment of splicing factors.<xref rid="jimd12697-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>, <xref rid="jimd12697-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> The desired properties can be generated by chemical modifications of backbone, sugar moiety and/or nucleoside.<xref rid="jimd12697-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>, <xref rid="jimd12697-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> Using a phosphorodiamidate morpholino oligomer (PMO), up to 41% restoration in mRNA level was observed after 72&#8208;h transfection in patient&#8208;derived lymphoblastoid, with significant increase in AADC protein and 5HT levels.<xref rid="jimd12697-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref> However, two new out&#8208;of&#8208;frame isoforms arouse, indicating the need to refine and/or use of combinatory ASOs to ensure appropriate splicing to minimise the risk of off&#8208;target effects.</p></sec><sec id="jimd12697-sec-0004"><label>2.2</label><title>Pyruvoyltetrahydropterin synthase deficiency</title><p>Pyruvoyltetrahydropterin synthase (PTPS) is the second step of BH<sub>4</sub> synthesis from GTP.<xref rid="jimd12697-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref> It is the most common BH<sub>4</sub> disorder identified by newborn screening (due to the presence of hyperphenylalaninaemia). Pyruvoyltetrahydropterin synthase deficiency (PTPSD) (OMIM #261140) has a broad phenotypic spectrum and can be biochemically characterised into mild and severe forms with reduction of HVA and 5&#8208;HIAA, which generally requires BH<sub>4</sub> and NT precursor supplementations with variable response.<xref rid="jimd12697-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jimd12697-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> One hundred ninety&#8208;nine autosomal recessive variants of the <italic toggle="yes">PTS</italic> gene, located at 11q22.3&#8208;23.3, have been identified, including 115 missense and 26 splicing substitutions; protein structures, particularly active site BH<sub>4</sub> binding region, are known to be disrupted.<xref rid="jimd12697-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>, <xref rid="jimd12697-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> To address the genetic defect, a retroviral (RV) gene transfer and two ASO strategies have been evaluated in patients fibroblasts. In PTPSD patients, low biopterin and high neopterin are observed; following Moloney murine leukaemia virus (MLV)&#8208;based RV transfection, PTPS enzyme activity and a trend for pterin normalisation was observed in all three patient fibroblast lines.<xref rid="jimd12697-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref> However, a potential translation challenge is that MLV vectors are inefficient in transducing slowly or non&#8208;dividing cells, as well as concerns about insertional mutagenesis.<xref rid="jimd12697-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref> Splice site variants can lead to aberrant intron inclusion (pseudoexons), as mediated via mechanisms such as novel 5&#8242; or 3&#8242; splice site, and influencing splice enhancer/silencer.<xref rid="jimd12697-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref> Therefore, ASO blockage of these cryptic splice sites could facilitate the expression of more functional proteins.<xref rid="jimd12697-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref> The two approaches utilised different ASO chemistries, specifically PMO<xref rid="jimd12697-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> and 2&#8242;&#8208;<italic toggle="yes">O</italic>&#8208;methyl phosphorothioate,<xref rid="jimd12697-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref> to block the recruitment of splicing factors for pathogenic pseudoexon production. Splice site&#8208;targeted ASOs were able to rescue three deep intronic mutations, which normally result in extra amino acid insertions, premature termination, and frameshift,<xref rid="jimd12697-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref> in patients' fibroblasts on mRNA and protein levels.<xref rid="jimd12697-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref> A further study on another intron 2 variant provided evidence that the same ASO can be used in variants affecting the same region, such as a common splice site or regulatory binding motifs.<xref rid="jimd12697-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref>
</p></sec></sec><sec id="jimd12697-sec-0005"><label>3</label><title>NT TRANSPORT</title><sec id="jimd12697-sec-0006"><label>3.1</label><title>Dopamine transporter deficiency syndrome</title><p>DAT is vital in regulating DA neurotransmission by reuptake of extracellular DA into midbrain dopaminergic (mDA) neurons, thereby regulating mDA excitability.<xref rid="jimd12697-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> DAT belongs to the solute carrier (SLC) 6 family, and co&#8208;transports Na<sup>+</sup> and Cl<sup>&#8722;</sup> along electrochemical gradients, to drive DA translocation against a concentration gradient via alternating access.<xref rid="jimd12697-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref>, <xref rid="jimd12697-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref> Gene variants have been implicated in PD, attention deficit hyperactivity disorder, autism and neuropsychiatric disorders.<xref rid="jimd12697-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref>, <xref rid="jimd12697-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref>, <xref rid="jimd12697-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> DTDS (OMIM #613135) results from biallelic loss&#8208;of&#8208;function mutations in <italic toggle="yes">SLC6A3</italic>. Classical DTDS is an infantile&#8208;onset, progressive motor disorder, with symptoms including hyperkinesia, orolingual dyskinesia, parkinsonism&#8208;dystonia and ocular flutter; atypical juvenile and adult&#8208;onset forms are also reported with a less aggressive disease course, and associated with higher residual DAT function.<xref rid="jimd12697-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jimd12697-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref>, <xref rid="jimd12697-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref> Evidence of neurodegeneration by DAT&#8208;single&#8208;photon emission computed tomography (SPECT) was observed in two atypical adult patients.<xref rid="jimd12697-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref>, <xref rid="jimd12697-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref> There is one adult case where autism spectrum disorder and PD are associated with a dominant&#8208;negative variant identified via exome sequencing.<xref rid="jimd12697-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref> In DTDS, loss of DAT function results in extraneuronal DA accumulation, leading to elevated CSF HVA but normal 5&#8208;HIAA.<xref rid="jimd12697-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref> Little benefit from pharmacological treatments is observed in patients<xref rid="jimd12697-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>; whilst pharmacochaperones could potentially correct mutation&#8208;related protein folding defects and DAT surface expression,<xref rid="jimd12697-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref> such approaches are mutation&#8208;specific, as opposed to a gene supplementation strategy, which could treat a broader spectrum of DTDS patients.</p><p>DAT&#8208;knockout (KO) mice recapitulate major human DTDS motor features, including progressive motor deficits, dyskinesia, tremors and metabolic profiles of high HVA and low DA; shortened lifespan with parkinsonism and reduced TH levels were also found in these mice.<xref rid="jimd12697-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref>, <xref rid="jimd12697-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref>, <xref rid="jimd12697-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref> A dual rAAV2/10 strategy, utilising Cre/LoxP system (FLEX switch<xref rid="jimd12697-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref>) for specific DA neuronal expression, was evaluated in adult post&#8208;natal (P70) DAT&#8208;KO mice.<xref rid="jimd12697-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> Briefly, the GOI (mouse <italic toggle="yes">Slc6a3</italic> or reporter gene), in inverted antisense orientation, was put into a double&#8208;inverted open reading frame containing two pairs of reciprocally orientated LoxP sites, driven by a ubiquitous (CMV) promoter and packaged as the first rAAV. The second rAAV contains a target cell/ tissue&#8208;specific promoter (midbrain DA neuronal promoter, rat TH<xref rid="jimd12697-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref>) to deliver Cre&#8208;recombinase, which can recognise the LoxP sites and inverse the GOI sequence, therefore allowing transgene expression.<xref rid="jimd12697-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref>, <xref rid="jimd12697-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref> Bilateral stereotactic SN injections of the two vectors, approximately at 5&#8201;&#215;&#8201;10<sup>9</sup>vg each, resulted in DAT expression and significant improvements in striatal extracellular DA levels and restoration of TH in the dorsal striatum.<xref rid="jimd12697-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref> Further behavioural, survival, tissue and metabolite analyses showed significant improvements compared to reporter gene&#8208;treated KO, and in some, phenotype restoration was comparable to wild&#8208;type (WT). Whilst this approach has provided great proof&#8208;of&#8208;concept for rAAV&#8208;DAT gene therapy, the use of a murine transcript, P1 bacteriophage&#8208;derived Cre/LoxP, and potential Cre&#8208;related neurotoxicity<xref rid="jimd12697-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> will limit clinical translation.</p><p>Our group previously showed in mDA neurons derived from DTDS patient fibroblasts, DAT dysfunction is associated with TNF&#8208;&#945;&#8208;mediated apoptotic neurodegeneration, which was not seen in age&#8208;matched and isogenic lines.<xref rid="jimd12697-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref> Lentiviral transduction of human <italic toggle="yes">SLC6A3</italic> rescued DA uptake and prevented neurodegeneration. For proof&#8208;of&#8208;principle in vivo investigation, rAAV9&#8208;SLC6A3 driven under truncated human synapsin 1 (hSyn1) promoter was injected neonatally by ICV at 2&#8201;&#215;&#8201;10<sup>10</sup> and 2&#8201;&#215;&#8201;10<sup>11</sup>vg/pup in DAT&#8208;KO mice. Compared to untreated DAT&#8208;KO, low dose increased 1&#8208;year survival from 41% to 100%, restored body weight, locomotor behaviour, DA and HVA profiles, and striatal neuronal firing. Widespread, rostrocaudal transduction was observed, with no dose&#8208;dependent increase in target mDA neurons; rather, brain&#8208;wide overexpression in high&#8208;dose animals led to adverse events requiring euthanasia in 50%, cortical reactive astrogliosis, neuronal loss and vacuolation. Therefore, to combat these observed off&#8208;target effects, a more restricted rAAV2 was used to treat symptomatic DAT&#8208;KO at 4&#8201;weeks; 3&#8208;log dose&#8208;ranging (2&#8201;&#215;&#8201;10<sup>8</sup>&#8211;10<sup>10</sup>vg/mouse) showed a dose&#8208;dependent increase in mDA neurons, human DAT protein, mRNA, and vector genome copy in the midbrain, with evidence of anterograde transport to the striatum. All doses rescued foot fault to WT level, with high dosage 2&#8201;&#215;&#8201;10<sup>10</sup> demonstrating open field and vertical pole descent time equivalent to WT. No neuropathology was observed in with these dosages, delivery route and capsid. Gene therapy for DTDS has recently been granted orphan drug designation by EMA and rare paediatric disease designation by FDA, with a Phase 1/2/3 clinical trial currently being planned.<xref rid="jimd12697-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref>
</p></sec><sec id="jimd12697-sec-0007"><label>3.2</label><title>SLC6A1&#8208;related disorder (GABA transporter 1&#8208;related myotonic&#8208;astatic epilepsy)</title><p>GABA transporter (GAT)&#8208;1 and &#8208;3 are the major GATs which are widely expressed in different cell types throughout the brain; GAT&#8208;1, encoded by <italic toggle="yes">SLC6A1</italic> on chromosome 3, is mainly localised to axonal terminals of GABAergic neurons and astrocytes.<xref rid="jimd12697-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>, <xref rid="jimd12697-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref> Myoclonic astatic epilepsy (OMIM #616421), caused by haploinsufficiency of <italic toggle="yes">SLC6A1</italic>, is a developmental and epileptic encephalopathy, associated with myoclonic&#8211;astatic and absence seizures, intellectual disability, autism spectrum disorder, and hypotonia in early years of life.<xref rid="jimd12697-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref>, <xref rid="jimd12697-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref> Around 120 patients have been published.<xref rid="jimd12697-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref> Loss&#8208;of&#8208;function <italic toggle="yes">SLC6A1</italic> variants lead to impaired protein trafficking and GABA transport activity; increased extracellular and reduced intracellular GABA levels are postulated to cause tonic and phasic inhibitions.<xref rid="jimd12697-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref>, <xref rid="jimd12697-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref> Given GABA's role in brain development from the early embryonic stage until maturity,<xref rid="jimd12697-bib-0121" ref-type="bibr">
<sup>121</sup>
</xref> restoration of GAT&#8208;1 expression with gene therapy may be beneficial over current symptomatic treatments.</p><p>TSHA&#8208;103, a scAAV9 driving codon&#8208;optimised copy of human <italic toggle="yes">SLC6A1</italic>, is currently in preclinical development by Taysha Gene Therapies.<xref rid="jimd12697-bib-0122" ref-type="bibr">
<sup>122</sup>
</xref> In a homozygous <italic toggle="yes">SLC6A1</italic>&#8208;KO mice model, neonatal ICV delivery at 3&#8201;&#215;&#8201;10<sup>11</sup>vg/pup of two constructs driven by either a ubiquitous (JeT) or a neuronal&#8208;specific (MeP) promoter significantly reduced seizure burden. Behavioural improvements were only noted in the neuronal&#8208;specific version. Furthermore, adverse effects were observed, including higher mortality with the ubiquitous promoter.<xref rid="jimd12697-bib-0123" ref-type="bibr">
<sup>123</sup>
</xref> For clinical translation, older mice were treated IT at 7&#8211;7.5&#8201;&#215;&#8201;10<sup>11</sup>vg/mouse, with lower cortical expression than neonatal ICV but was well&#8208;tolerated for up to 1&#8201;year. However, only modest efficacy in behavioural tests was observed when treated at P7&#8211;10, with no improvement in the P28&#8211;35 group.<xref rid="jimd12697-bib-0123" ref-type="bibr">
<sup>123</sup>
</xref> To evaluate whether therapeutic efficacy is linked to transduction efficiency or earlier intervention, AAV&#8208;PHP.eB, a neurotropic variant of AAV9, was used for IV injection in P23 mice.<xref rid="jimd12697-bib-0124" ref-type="bibr">
<sup>124</sup>
</xref> Seizure reduction was not achieved at any of the three doses (ranging from 2&#8201;&#215;&#8201;10<sup>10</sup> to 1&#8201;&#215;&#8201;10<sup>12</sup>vg/mouse). This suggests both a narrow therapeutic window and that further expression optimisation is required.</p></sec></sec><sec id="jimd12697-sec-0008"><label>4</label><title>NT DEGRADATION</title><sec id="jimd12697-sec-0009"><label>4.1</label><title>Succinic semialdehyde dehydrogenase deficiency</title><p>Succinic semialdehyde dehydrogenase (SSADH) is a systemically expressed mitochondrial enzyme, with major expression in the brain and liver.<xref rid="jimd12697-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref> In healthy individuals, synaptic GABA is transported into astrocytes by GAT, converted to succinic semialdehyde by GABA transaminase (GABA&#8208;T), then oxidised in tandem by SSADH to succinate, a substrate of the TCA cycle.<xref rid="jimd12697-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref> In SSADHD (OMIM #271980), biallelic loss&#8208;of&#8208;function mutations in the encoding <italic toggle="yes">ALDH5A1</italic> (6p22.3) gene result in the cytosolic conversion of succinic semialdehyde to &#947;&#8208;hydroxybutyrate (GHB), a neuromodulator with neurotoxic properties, instead.<xref rid="jimd12697-bib-0126" ref-type="bibr">
<sup>126</sup>
</xref> Excess accumulations of GABA, GHB and other GABA metabolites are found in brain and body fluids, but the exact pathophysiology remains to be elucidated.<xref rid="jimd12697-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref> Clinical symptoms, including hypotonia, developmental delay, epilepsy, and behavioural and sleep disturbances, manifest in early childhood<xref rid="jimd12697-bib-0126" ref-type="bibr">
<sup>126</sup>
</xref>; age&#8208;dependent association in symptom severity and seizure types have been described.<xref rid="jimd12697-bib-0127" ref-type="bibr">
<sup>127</sup>
</xref> Post&#8208;mortem study of one patient also found amino acid, phospholipid, and NT disturbances.<xref rid="jimd12697-bib-0128" ref-type="bibr">
<sup>128</sup>
</xref> No effective treatment currently exists to address the underlying deficiency and downstream metabolic sequelae.</p><p>As the liver also expresses high levels of SSADH, and central and peripheral GHB rapidly equilibrates,<xref rid="jimd12697-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref> a liver&#8208;directed adenoviral approach was evaluated in a mouse SSADH&#8208;KO model.<xref rid="jimd12697-bib-0129" ref-type="bibr">
<sup>129</sup>
</xref> These mice recapitulate metabolic features observed in humans but have more severe phenotypes, with reduced survival up to P26 due to status epilepticus.<xref rid="jimd12697-bib-0130" ref-type="bibr">
<sup>130</sup>
</xref> Using a first&#8208;generation E1&#8208;deleted adenovirus, human SSADH cDNA was delivered under a potent Rous sarcoma virus promoter intraperitoneally (IP) at P10 at three doses (4.5&#8201;&#215;&#8201;10<sup>8</sup>, 1&#8201;&#215;&#8201;10<sup>10</sup>, 1&#8201;&#215;&#8201;10<sup>11</sup> viral particles [vp]), and retro&#8208;orbitally (RO) at P13 with 1&#8201;&#215;&#8201;10<sup>11</sup>vp.<xref rid="jimd12697-bib-0129" ref-type="bibr">
<sup>129</sup>
</xref> Extension in survival was observed in all treatment groups, highest by 39.3% in the 4.5&#8201;&#215;&#8201;10<sup>8</sup> IP group. For tissue analysis, different sets of mice were injected and tissues were collected at different timepoints; at 72&#8201;h post&#8208;injection, higher hepatic SSADH enzymatic activity was achieved by RO (maximum ~20%) than IP. RO&#8208;treated also had GHB reduction in the liver, brain, kidney and serum, but restricted to the liver only for IP. In treated mice that survived beyond 1&#8201;month, mRNA but not SSADH enzyme activity was detected. Neonatal (P0) IP injections reduced liver GHB for up to 8&#8201;days, but was accompanied by unexplained rebound elevation in the brain. Overall, the vector appeared to be safe, but transient expression secondary to immunogenicity, dividing nature of hepatocytes, and hepatic&#8208;only targeting may have limited its effectiveness, all factors that need to be addressed for future clinical translation.</p></sec></sec><sec sec-type="discussion" id="jimd12697-sec-0010"><label>5</label><title>DISCUSSION</title><p>Effective management of rare diseases, including IEM, requires accurate diagnoses and disease&#8208;modifying treatments. For IEM&#8208;NT, only a handful of disorders are identified through newborn screening and there can often be diagnostic delay. The clinical responses to existing small molecule pharmacotherapies are variable from disease to disease, with some evidence showing that earlier treatment initiation is associated with better outcomes for some IEM.<xref rid="jimd12697-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jimd12697-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref> Advances in genome/exome sequencing, transcriptomics, and other complementary diagnostic techniques has significantly improved the diagnostic rate of rare diseases patients.<xref rid="jimd12697-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref> Other avenues include building on existing newborn screening programmes, which are either already adopted or being currently validated for AADCD. In Taiwan, Italy, Germany and Brazil, the diagnostic utility of detecting high levels of 3&#8208;<italic toggle="yes">O</italic>&#8208;methyldopa in dried blood spots via mass spectrometry is under evaluation.<xref rid="jimd12697-bib-0131" ref-type="bibr">
<sup>131</sup>
</xref>, <xref rid="jimd12697-bib-0132" ref-type="bibr">
<sup>132</sup>
</xref>, <xref rid="jimd12697-bib-0133" ref-type="bibr">
<sup>133</sup>
</xref>, <xref rid="jimd12697-bib-0134" ref-type="bibr">
<sup>134</sup>
</xref> In terms of treatments, gene therapy, both preclinically and clinically, is proving to be a promising disease&#8208;modifying approach for many IEM.<xref rid="jimd12697-bib-0135" ref-type="bibr">
<sup>135</sup>
</xref>, <xref rid="jimd12697-bib-0136" ref-type="bibr">
<sup>136</sup>
</xref> Other technologies, such as gene&#8208;editing, utilises machinery such as zinc&#8208;finger nucleases and CRISPR&#8208;Cas (clustered regularly interspaced short palindromic repeat&#8208;Cas&#8208;associated nucleases), delivered in vivo as proteins in nanoparticle delivery systems or nucleic acid in AAV, are being evaluated preclinically and clinically for some IEM conditions.<xref rid="jimd12697-bib-0137" ref-type="bibr">
<sup>137</sup>
</xref>, <xref rid="jimd12697-bib-0138" ref-type="bibr">
<sup>138</sup>
</xref>
</p><p>As the majority of IEM&#8208;NT are monogenic and autosomal recessive, AAV gene supplementation therapy is an attractive, one&#8208;off, disease&#8208;modifying treatment for many of these rare diseases. This offers some advantages over ASOs that require repeated direct administration into CNS, and avoids the need to tailor guide RNAs for each pathogenic mutation in gene editing. Safety and tolerability of NT&#8208;related gene therapies in humans have been evaluated with PD, and efficacy has been clearly shown in AADCD by positive trial outcomes culminating for putaminal&#8208;delivered<xref rid="jimd12697-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="jimd12697-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> and midbrain&#8208;delivered<xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> gene therapy, with Upstaza&#8482; receiving EMA and MHRA approval in 2022.</p><p>With gene therapies now reaching the clinical arena, there are new aspects to consider as we learn more about AAV gene therapies, for instance, new safety concerns, optimal therapeutic window, ease of global access to treatment, and how to navigate multiple treatment options for each IEM&#8208;NT. Specific safety concerns of CNS AAV gene therapies regarding dorsal root ganglion toxicity, with neuronal degeneration and axonopathy associated with a variety of rAAV capsids and promoters, having been attributed to transgene overexpression in NHP.<xref rid="jimd12697-bib-0139" ref-type="bibr">
<sup>139</sup>
</xref>, <xref rid="jimd12697-bib-0140" ref-type="bibr">
<sup>140</sup>
</xref> Dose&#8208;associated toxicity via ITH administration, with highest&#8208;dosed NHP at 3.2&#8201;&#215;&#8201;10<sup>12</sup>vg of a rAAVrh8 vector expressing Hex&#945;/&#946;, showed ataxia and general weakness at 2&#8211;3&#8201;weeks and requiring euthanasia due to apathy by 1&#8201;month.<xref rid="jimd12697-bib-0141" ref-type="bibr">
<sup>141</sup>
</xref> To date, the clinical relevance of DRG toxicity in humans has yet to be elucidated, with no treatment&#8208;related DRG toxicity reported in Zolgensma&#174;'s trials and global access programme.<xref rid="jimd12697-bib-0142" ref-type="bibr">
<sup>142</sup>
</xref>, <xref rid="jimd12697-bib-0143" ref-type="bibr">
<sup>143</sup>
</xref>, <xref rid="jimd12697-bib-0144" ref-type="bibr">
<sup>144</sup>
</xref> Moreover, tight control of NT systems may imply a narrow therapeutic dosing window (i.e., between efficacy and toxicity), as seen in our DTDS preclinical gene therapy study, whereby a 10&#8208;fold increase in dose resulted in unexpected weight loss and motor disturbances related to off&#8208;target effects.<xref rid="jimd12697-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref> Careful dose calibration in achieving efficacy and minimal toxicity can be challenging, given the irreversibility of AAV gene therapy, the long persistence of AAV genome (up to 15&#8201;years in NHP for PD<xref rid="jimd12697-bib-0145" ref-type="bibr">
<sup>145</sup>
</xref>), and potential epigenetic silencing of rAAV genomes in vitro<xref rid="jimd12697-bib-0146" ref-type="bibr">
<sup>146</sup>
</xref>, with relevance in human patients yet to be determined. As described previously, strategies to finetune expression might include optimisation of delivery routes, capsid, promoters, and/or RE.<xref rid="jimd12697-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</p><p>Specific to IEM&#8208;NT disorders, we must recognise that NTs are vital in neurodevelopment from the embryonic stages,<xref rid="jimd12697-bib-0147" ref-type="bibr">
<sup>147</sup>
</xref> so one consideration is how to diagnose patients at the earliest opportunity, and ensure that treatment is administered within the optimal treatment window for maximal therapeutic efficacy. In BH<sub>4</sub> deficiencies, it is already recognised that earlier treatment is linked to better cognitive outcome, but it is unclear whether the developmental trajectory can be completely restored to normal.<xref rid="jimd12697-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jimd12697-bib-0148" ref-type="bibr">
<sup>148</sup>
</xref> Similarly, AADC gene therapy trials suggest younger patients achieved better motor scores, and brain structure improvements. Notably, all patients who gained the ability to walk were treated by ~4&#8201;years of age.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref> In THD, mild&#8211;moderate cognitive delay is observed in a significant portion of patients who otherwise have a beneficial response to <sc>l</sc>&#8208;DOPA.<xref rid="jimd12697-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Abnormalities in neuronal and synaptic development were observed in a miscarried foetus with THD as early as 16&#8201;weeks gestation.<xref rid="jimd12697-bib-0149" ref-type="bibr">
<sup>149</sup>
</xref> In addition, for IEM&#8208;NT that affects more than one NT, such as the case for AADC, careful evaluations are needed in designing the target(s) of the gene therapy product to achieve maximum patient benefits. 5&#8208;HT is produced in raphe nuclei throughout the brainstem; current strategies targeting the putamen or midbrain might not be directly addressing 5&#8208;HT deficiency, as CSF 5&#8208;HT metabolite (5&#8208;HIAA) was not significantly increased after delivery.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> Although significant symptomatic improvements were seen in the carer&#8208;reported questionnaire,<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref> implications in the longer&#8208;term management of these patients are still unclear. Moreover, interactions within different components of the NT synthesis pathway can be altered in disease state, with the exact mechanisms and long&#8208;term implications not fully understood. One example is different BH<sub>4</sub> deficiency murine models, namely sepiapterin reductase,<xref rid="jimd12697-bib-0150" ref-type="bibr">
<sup>150</sup>
</xref> PTPS,<xref rid="jimd12697-bib-0151" ref-type="bibr">
<sup>151</sup>
</xref> and GCH1,<xref rid="jimd12697-bib-0152" ref-type="bibr">
<sup>152</sup>
</xref> where reduction in TH protein levels, particularly in striatum, were observed, impacting foetal DA circuit development.<xref rid="jimd12697-bib-0153" ref-type="bibr">
<sup>153</sup>
</xref> Normal TH levels, therefore, appear critical for psychomotor function and DA system maturation.<xref rid="jimd12697-bib-0154" ref-type="bibr">
<sup>154</sup>
</xref> It may be that gene therapies for IEM&#8208;NT would be most efficacious in younger patients, providing a case for earlier diagnosis and potential foetal/newborn screening for IEM&#8208;NT. More extensive natural history studies of these rare disorders will, therefore, be invaluable when developing new therapies to better inform about the timing of gene delivery.</p><p>Another important consideration is accessibility for patients; the list price for Upstaza&#8482; is &#163;3 million (~&#8364;3.4 million),<xref rid="jimd12697-bib-0155" ref-type="bibr">
<sup>155</sup>
</xref> whereas Zolgensma&#174; for SMA is &#8364;1.95 million. Discount negotiations, reimbursement schemes, and cost&#8208;effectiveness calculations measured by quality&#8208;adjusted life year vary by country,<xref rid="jimd12697-bib-0156" ref-type="bibr">
<sup>156</sup>
</xref> and so regional differences are likely expected. Part of the cost is attributed to the complexities of AAV GMP manufacturing and downstream processing.<xref rid="jimd12697-bib-0157" ref-type="bibr">
<sup>157</sup>
</xref> Moreover, the need for pre&#8208; and post&#8208;administration monitoring and establishment of long&#8208;term efficacy and safety profiles (10&#8201;years required for Upstaza&#8482;),<xref rid="jimd12697-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref> likely means only specialised hospital sites can provide these therapies, potentially limiting broader access.</p><p>In the rapidly growing space of advanced therapies, multiple strategies will be approved and licenced, for the same disease, such as in the case of SMA. For AADCD, three gene therapy clinical trials and Upstaza&#8482; utilise different AAV gene supplementation strategies. However, the clinical impact of the different brain targeting, dosage, capsids, and construct designs (with differing RE) is not yet clear. Putaminally delivered DA restoration in the prefrontal cortico&#8208;putaminal network was found to be important for motor improvement,<xref rid="jimd12697-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> and directly targeting the mDA neurons may improve or restore physiological DA homeostasis, and potentially protect from DA&#8208;induced oxidative stress, that may occur with putaminal dopamine synthesis. Moreover, expression profiles vary with different capsids, promoters, and RE. AAV2 shows properties of anterograde transport with predominant neuronal transduction, whilst AAV9 shows both anterograde and retrograde transport, and neuronal and glial transduction.<xref rid="jimd12697-bib-0158" ref-type="bibr">
<sup>158</sup>
</xref> The AADCD clinical trials (where disclosed) have used ubiquitous CMV promoters, yet no head&#8208;to&#8208;head in vivo studies have been performed to compare construct expression efficiency or other differences (Figure&#160;<xref rid="jimd12697-fig-0002" ref-type="fig">2</xref>), which may result in variable mRNA levels and stability. From a clinical perspective, different inclusion ages (Upstaza&#8482; 18&#8201;months and over, Kojima et al.<xref rid="jimd12697-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref>, <xref rid="jimd12697-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> and Pearson et al.<xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>, <xref rid="jimd12697-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> 4&#8201;years and over, VGN&#8208;R09b<xref rid="jimd12697-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> 2&#8211;8&#8201;years old), variable baseline disease severity, and relatively small patient groups may make direct comparison difficult, as well as the use of different outcome measures (e.g., PDMS&#8208;2 vs. GMFM&#8208;88). Over time, it would be of utmost patient benefit to have an international, standardised approach from pre&#8208;screening to post&#8208;gene therapy surveillance, using appropriate disease&#8208;specific registries, to consolidate clinical data, allowing for thorough treatment evaluations, especially in rare diseases like IEM&#8208;NT.<xref rid="jimd12697-bib-0159" ref-type="bibr">
<sup>159</sup>
</xref>
</p><p>Adverse effects of gene therapy for IEM&#8208;NT would likely depend on the NT pathway(s) targeted. For example, for most AADCD patients, transient dyskinesia is expected around 4&#8201;weeks post&#8208;therapy. This is likely a result of AAV&#8208;driven AADC&#8208;related DA production, leading to potential hypersensitivity of DA receptor, and should resolve as DA homeostasis stabilises.<xref rid="jimd12697-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="jimd12697-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Management of these dyskinesias depends on trial protocol or local guidelines and should be overseen by a clinician with expertise in this area. Generally, treatment should be initiated if the movements interfere with routine care, function, comfort, sitting or sleeping. Any DA agonists or monoamine oxide inhibitors may be tapered and weaned off, as necessary.<xref rid="jimd12697-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>, <xref rid="jimd12697-bib-0159" ref-type="bibr">
<sup>159</sup>
</xref> Agents such as amantadine, benzodiazepines, gabapentin, clonidine or even tetrabenazine may be considered for the short&#8208;term management of this transient dyskinesia.<xref rid="jimd12697-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>, <xref rid="jimd12697-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Some patients will need more intensive medical management within intensive care or high dependency.</p><p>Overall, with the rapid innovations in vector technology and a better understanding of pathophysiology and molecular diagnosis, gene therapy for IEM&#8208;NT is a growing field that could soon become a clinical reality for many diseases. Early diagnosis and treatment would likely be key for IEM&#8208;NT, and accessibility would be fundamental in achieving the full potential and clinical impact of these new treatments globally.</p></sec><sec id="jimd12697-sec-0011"><title>AUTHOR CONTRIBUTIONS</title><p>Wing Sum Chu drafted and revised the manuscript. Joanne Ng, Simon N. Waddington and Manju A. Kurian gave substantial intellectual input in manuscript critique and revision.</p></sec><sec sec-type="COI-statement" id="jimd12697-sec-0013"><title>CONFLICT OF INTEREST STATEMENT</title><p>Joanne Ng is an inventor on patent application titled Gene therapy for DTDS (GB2101958.3), has consultancy agreements with Albion Venture Capital, sponsored research agreements with Synpromics/Askbio Europe, Rocket Pharma, Helex Bio and Bloomsbury Genetic Therapies and holds equity in Bloomsbury Genetic Therapies. Simon N. Waddington is an inventor on patent application titled Gene therapy for DTDS (GB2101958.3), holds consultancy agreements with Biormarin and Albion Capital, has previous or existing consultancy agreements with ONO Pharmaceuticals, Synpromics Ltd., Reliance Biosciences, Codiak Biosciences, Takeda Pharmaceutical Company and LivaNova Plc., has sponsored research agreements with Synpromics/Askbio Europe Rocket Pharma, Helex Bio and is founder of Bloomsbury Genetic Therapies. Manju A. Kurian is an inventor on patent application titled Gene therapy for DTDS (GB2101958.3), was sponsored by Agilis to attend the AADC Deficiency International Advisory Board (2018), received honoraria for speaking at a PTC sponsored symposium (2023), and is founder of Bloomsbury Genetic Therapies. Wing Sum Chu declares no conflict of interest.</p></sec><sec id="jimd12697-sec-0016"><title>ETHICS STATEMENT</title><p>This article does not contain any studies with human or animal subjects performed by any of the authors.</p></sec></body><back><ack id="jimd12697-sec-0012"><title>ACKNOWLEDGEMENTS</title><p>We thank our funding support: Wellcome Intermediate Clinical Fellowship (WT098524MA to MAK), UK Medical Research Council (MRC) Clinical Research training fellowship (MR/K02342X/1 to JN), MRC Biomedical Catalyst Developmental Pathway Funding Scheme (MR/R015325/1 to SNW, MAK, JN), Great Ormond Street Hospital Children's Charity and the Rosetrees Trust, Robert Luff Foundation and John Black Foundation (V1284 and M576 to MAK, JN, SNW), NIHR Research Professorship (NIHR&#8208;RP&#8208;2016&#8208;07&#8208;019 to MAK) Sir Jules Thorn Award for Biomedical Research (MAK), and LifeArc Philanthropic fund (P2023&#8208;0002 to JN, MAK, SNW). The authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors.</p></ack><sec sec-type="data-availability" id="jimd12697-sec-0015"><title>DATA AVAILABILITY STATEMENT</title><p>Data sharing is not applicable to this article as no new data were created or analysed in this study.</p></sec><ref-list id="jimd12697-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="jimd12697-bib-0001"><label>1</label><mixed-citation publication-type="book" id="jimd12697-cit-0001"><string-name name-style="western"><surname>Nestler</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Hyman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Holtzman</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Malenka</surname><given-names>RC</given-names></string-name>. <part-title>Synaptic transmission</part-title>. <source>Molecular Neuropharmacology: A Foundation for Clinical Neuroscience, 3e</source>. <publisher-name>McGraw&#8208;Hill Education</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="jimd12697-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jimd12697-cit-0002"><string-name name-style="western"><surname>Opladen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cort&#232;s&#8208;Saladelafont</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Mastrangelo</surname><given-names>M</given-names></string-name>, et al. <article-title>The International Working Group on Neurotransmitter Related Disorders (iNTD): a worldwide research project focused on primary and secondary neurotransmitter disorders</article-title>. <source>Mol Genet Metab Rep</source>. <year>2016</year>;<volume>9</volume>:<fpage>61</fpage>&#8208;<lpage>66</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgmr.2016.09.006</pub-id><pub-id pub-id-type="pmid">27830117</pub-id><pub-id pub-id-type="pmcid">PMC5094101</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jimd12697-cit-0003"><string-name name-style="western"><surname>Pearl</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Capp</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Novotny</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>KM</given-names></string-name>. <article-title>Inherited disorders of neurotransmitters in children and adults</article-title>. <source>Clin Biochem</source>. <year>2005</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1051</fpage>&#8208;<lpage>1058</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.clinbiochem.2005.09.012</pub-id><pub-id pub-id-type="pmid">16298354</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jimd12697-cit-0004"><string-name name-style="western"><surname>Trist&#225;n&#8208;Noguero</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Garc&#237;a&#8208;Cazorla</surname><given-names>&#192;</given-names></string-name>. <article-title>Synaptic metabolism: a new approach to inborn errors of neurotransmission</article-title>. <source>J Inherit Metab Dis</source>. <year>2018</year>;<volume>41</volume>(<issue>6</issue>):<fpage>1065</fpage>&#8208;<lpage>1075</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10545-018-0235-7</pub-id><pub-id pub-id-type="pmid">30014210</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jimd12697-cit-0005"><string-name name-style="western"><surname>Meiser</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weindl</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hiller</surname><given-names>K</given-names></string-name>. <article-title>Complexity of dopamine metabolism</article-title>. <source>Cell Commun Signal</source>. <year>2013</year>;<volume>11</volume>:<elocation-id>34</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/1478-811X-11-34</pub-id><pub-id pub-id-type="pmid">23683503</pub-id><pub-id pub-id-type="pmcid">PMC3693914</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jimd12697-cit-0006"><string-name name-style="western"><surname>Joseph</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pidathala</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mallela</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Penmatsa</surname><given-names>A</given-names></string-name>. <article-title>Structure and gating dynamics of Na<sup>+</sup>/Cl<sup>&#8722;</sup> coupled neurotransmitter transporters</article-title>. <source>Front Mol Biosci</source>. <year>2019</year>;<volume>6</volume>:<elocation-id>80</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fmolb.2019.00080</pub-id><pub-id pub-id-type="pmid">31555663</pub-id><pub-id pub-id-type="pmcid">PMC6742698</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jimd12697-cit-0007"><string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Gissen</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Heales</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Clayton</surname><given-names>PT</given-names></string-name>. <article-title>The monoamine neurotransmitter disorders: an expanding range of neurological syndromes</article-title>. <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>(<issue>8</issue>):<fpage>721</fpage>&#8208;<lpage>733</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(11)70141-7</pub-id><pub-id pub-id-type="pmid">21777827</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jimd12697-cit-0008"><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Papandreou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Heales</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>. <article-title>Monoamine neurotransmitter disorders&#8212;clinical advances and future perspectives</article-title>. <source>Nat Rev Neurol</source>. <year>2015</year>;<volume>11</volume>(<issue>10</issue>):<fpage>567</fpage>&#8208;<lpage>584</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrneurol.2015.172</pub-id><pub-id pub-id-type="pmid">26392380</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jimd12697-cit-0009"><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heales</surname><given-names>SJR</given-names></string-name>, <string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>. <article-title>Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders</article-title>. <source>Paediatr Drugs</source>. <year>2014</year>;<volume>16</volume>(<issue>4</issue>):<fpage>275</fpage>&#8208;<lpage>291</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40272-014-0079-z</pub-id><pub-id pub-id-type="pmid">25011953</pub-id><pub-id pub-id-type="pmcid">PMC4102824</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jimd12697-cit-0010"><string-name name-style="western"><surname>H&#252;bschmann</surname><given-names>OK</given-names></string-name>, <string-name name-style="western"><surname>Horvath</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cort&#232;s&#8208;Saladelafont</surname><given-names>E</given-names></string-name>, et al. <article-title>Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>5529</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-25515-5</pub-id><pub-id pub-id-type="pmid">34545092</pub-id><pub-id pub-id-type="pmcid">PMC8452745</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jimd12697-cit-0011"><string-name name-style="western"><surname>Keller</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brennenstuhl</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kuseyri H&#252;bschmann</surname><given-names>O</given-names></string-name>, et al. <article-title>Assessment of intellectual impairment, health&#8208;related quality of life, and behavioral phenotype in patients with neurotransmitter related disorders: data from the iNTD registry</article-title>. <source>J Inherit Metab Dis</source>. <year>2021</year>;<volume>44</volume>(<issue>6</issue>):<fpage>1489</fpage>&#8208;<lpage>1502</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12416</pub-id><pub-id pub-id-type="pmid">34245036</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jimd12697-cit-0012"><string-name name-style="western"><surname>H&#252;bschmann</surname><given-names>OK</given-names></string-name>, <string-name name-style="western"><surname>Mohr</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Friedman</surname><given-names>J</given-names></string-name>, et al. <article-title>Brain MR patterns in inherited disorders of monoamine neurotransmitters: an analysis of 70 patients</article-title>. <source>J Inherit Metab Dis</source>. <year>2021</year>;<volume>44</volume>(<issue>4</issue>):<fpage>1070</fpage>&#8208;<lpage>1082</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12360</pub-id><pub-id pub-id-type="pmid">33443316</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jimd12697-cit-0013"><string-name name-style="western"><surname>Alfonsi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Stephan&#8208;Otto</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cort&#232;s&#8208;Saladelafont</surname><given-names>E</given-names></string-name>, et al. <article-title>Volumetric study of brain MRI in a cohort of patients with neurotransmitter disorders</article-title>. <source>Neuroradiology</source>. <year>2022</year>;<volume>64</volume>(<issue>11</issue>):<fpage>2179</fpage>&#8208;<lpage>2190</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00234-022-02989-8</pub-id><pub-id pub-id-type="pmid">35662359</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jimd12697-cit-0014"><string-name name-style="western"><surname>Marwaha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Knowles</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Ashley</surname><given-names>EA</given-names></string-name>. <article-title>A guide for the diagnosis of rare and undiagnosed disease: beyond the exome</article-title>. <source>Genome Med</source>. <year>2022</year>;<volume>14</volume>(<issue>1</issue>):<elocation-id>23</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13073-022-01026-w</pub-id><pub-id pub-id-type="pmid">35220969</pub-id><pub-id pub-id-type="pmcid">PMC8883622</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jimd12697-cit-0015"><string-name name-style="western"><surname>Opladen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>L&#243;pez&#8208;Laso</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Cort&#232;s&#8208;Saladelafont</surname><given-names>E</given-names></string-name>, et al. <article-title>Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH<sub>4</sub>) deficiencies</article-title>. <source>Orphanet J Rare Dis</source>. <year>2020</year>;<volume>15</volume>:<elocation-id>126</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13023-020-01379-8</pub-id><pub-id pub-id-type="pmid">32456656</pub-id><pub-id pub-id-type="pmcid">PMC7251883</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jimd12697-cit-0016"><string-name name-style="western"><surname>Wassenberg</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Molero&#8208;Luis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jeltsch</surname><given-names>K</given-names></string-name>, et al. <article-title>Consensus guideline for the diagnosis and treatment of aromatic <sc>l</sc>&#8208;amino acid decarboxylase (AADC) deficiency</article-title>. <source>Orphanet J Rare Dis</source>. <year>2017</year>;<volume>12</volume>:<elocation-id>12</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13023-016-0522-z</pub-id><pub-id pub-id-type="pmid">28100251</pub-id><pub-id pub-id-type="pmcid">PMC5241937</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jimd12697-cit-0017"><string-name name-style="western"><surname>Willemsen</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Verbeek</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Kamsteeg</surname><given-names>E&#8208;J</given-names></string-name>, et al. <article-title>Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis</article-title>. <source>Brain</source>. <year>2010</year>;<volume>133</volume>(<issue>6</issue>):<fpage>1810</fpage>&#8208;<lpage>1822</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awq087</pub-id><pub-id pub-id-type="pmid">20430833</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jimd12697-cit-0018"><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>E</given-names></string-name>, et al. <article-title>Dopamine transporter deficiency syndrome: phenotypic Spectrum from infancy to adulthood</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>(<issue>4</issue>):<fpage>1107</fpage>&#8208;<lpage>1119</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awu022</pub-id><pub-id pub-id-type="pmid">24613933</pub-id><pub-id pub-id-type="pmcid">PMC3959557</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jimd12697-cit-0019"><string-name name-style="western"><surname>Opladen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>GF</given-names></string-name>, <string-name name-style="western"><surname>Blau</surname><given-names>N</given-names></string-name>. <article-title>An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia</article-title>. <source>J Inherit Metab Dis</source>. <year>2012</year>;<volume>35</volume>(<issue>6</issue>):<fpage>963</fpage>&#8208;<lpage>973</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10545-012-9506-x</pub-id><pub-id pub-id-type="pmid">22729819</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jimd12697-cit-0020"><string-name name-style="western"><surname>Bulcha</surname><given-names>JT</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>PWL</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>. <article-title>Viral vector platforms within the gene therapy landscape</article-title>. <source>Signal Transduct Target Ther</source>. <year>2021</year>;<volume>6</volume>:<elocation-id>53</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41392-021-00487-6</pub-id><pub-id pub-id-type="pmid">33558455</pub-id><pub-id pub-id-type="pmcid">PMC7868676</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jimd12697-cit-0021"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Tai</surname><given-names>PWL</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>G</given-names></string-name>. <article-title>Adeno&#8208;associated virus vector as a platform for gene therapy delivery</article-title>. <source>Nat Rev Drug Discov</source>. <year>2019</year>;<volume>18</volume>(<issue>5</issue>):<fpage>358</fpage>&#8208;<lpage>378</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-019-0012-9</pub-id><pub-id pub-id-type="pmid">30710128</pub-id><pub-id pub-id-type="pmcid">PMC6927556</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jimd12697-cit-0022"><string-name name-style="western"><surname>Earley</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Conatser</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Lue</surname><given-names>VM</given-names></string-name>, et al. <article-title>Adeno&#8208;associated virus serotype&#8208;specific inverted terminal repeat sequence role in vector transgene expression</article-title>. <source>Hum Gene Ther</source>. <year>2020</year>;<volume>31</volume>(<issue>3&#8208;4</issue>):<fpage>151</fpage>&#8208;<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2019.274</pub-id><pub-id pub-id-type="pmid">31914802</pub-id><pub-id pub-id-type="pmcid">PMC7047122</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jimd12697-cit-0023"><string-name name-style="western"><surname>Martino</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Markusic</surname><given-names>DM</given-names></string-name>, et al. <article-title>The genome of self&#8208;complementary adeno&#8208;associated viral vectors increases toll&#8208;like receptor 9&#8208;dependent innate immune responses in the liver</article-title>. <source>Blood</source>. <year>2011</year>;<volume>117</volume>(<issue>24</issue>):<fpage>6459</fpage>&#8208;<lpage>6468</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2010-10-314518</pub-id><pub-id pub-id-type="pmid">21474674</pub-id><pub-id pub-id-type="pmcid">PMC3123017</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jimd12697-cit-0024"><string-name name-style="western"><surname>Wu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>T&#246;pfer</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>S&#8208;W</given-names></string-name>, et al. <article-title>Self&#8208;complementary AAVs induce more potent transgene product&#8208;specific immune responses compared to a single&#8208;stranded genome</article-title>. <source>Mol Ther</source>. <year>2012</year>;<volume>20</volume>(<issue>3</issue>):<fpage>572</fpage>&#8208;<lpage>579</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mt.2011.280</pub-id><pub-id pub-id-type="pmid">22186792</pub-id><pub-id pub-id-type="pmcid">PMC3293612</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jimd12697-cit-0025"><string-name name-style="western"><surname>Bedbrook</surname><given-names>CN</given-names></string-name>, <string-name name-style="western"><surname>Deverman</surname><given-names>BE</given-names></string-name>, <string-name name-style="western"><surname>Gradinaru</surname><given-names>V</given-names></string-name>. <article-title>Viral strategies for targeting the central and peripheral nervous systems</article-title>. <source>Annu Rev Neurosci</source>. <year>2018</year>;<volume>41</volume>(<issue>1</issue>):<fpage>323</fpage>&#8208;<lpage>348</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-neuro-080317-062048</pub-id><pub-id pub-id-type="pmid">29709207</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jimd12697-cit-0026"><string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></string-name>. <article-title>Engineering adeno&#8208;associated virus vectors for gene therapy</article-title>. <source>Nat Rev Genet</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>255</fpage>&#8208;<lpage>272</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41576-019-0205-4</pub-id><pub-id pub-id-type="pmid">32042148</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jimd12697-cit-0027"><string-name name-style="western"><surname>Challis</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Ravindra Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, et al. <article-title>Adeno&#8208;associated virus toolkit to target diverse brain cells</article-title>. <source>Annu Rev Neurosci</source>. <year>2022</year>;<volume>45</volume>(<issue>1</issue>):<fpage>447</fpage>&#8208;<lpage>469</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-neuro-111020-100834</pub-id><pub-id pub-id-type="pmid">35440143</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jimd12697-cit-0028"><string-name name-style="western"><surname>Lisowski</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Dane</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>K</given-names></string-name>, et al. <article-title>Selection and evaluation of clinically relevant AAV variants in a xenograft liver model</article-title>. <source>Nature</source>. <year>2014</year>;<volume>506</volume>(<issue>7488</issue>):<fpage>382</fpage>&#8208;<lpage>386</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12875</pub-id><pub-id pub-id-type="pmid">24390344</pub-id><pub-id pub-id-type="pmcid">PMC3939040</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jimd12697-cit-0029"><string-name name-style="western"><surname>George</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Monahan</surname><given-names>PE</given-names></string-name>, <string-name name-style="western"><surname>Eyster</surname><given-names>ME</given-names></string-name>, et al. <article-title>Multiyear factor VIII expression after AAV gene transfer for hemophilia A</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>385</volume>(<issue>21</issue>):<fpage>1961</fpage>&#8208;<lpage>1973</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2104205</pub-id><pub-id pub-id-type="pmid">34788507</pub-id><pub-id pub-id-type="pmcid">PMC8672712</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jimd12697-cit-0030"><string-name name-style="western"><surname>Zinn</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Pacouret</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khaychuk</surname><given-names>V</given-names></string-name>, et al. <article-title>In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector</article-title>. <source>Cell Rep</source>. <year>2015</year>;<volume>12</volume>(<issue>6</issue>):<fpage>1056</fpage>&#8208;<lpage>1068</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2015.07.019</pub-id><pub-id pub-id-type="pmid">26235624</pub-id><pub-id pub-id-type="pmcid">PMC4536165</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jimd12697-cit-0031"><string-name name-style="western"><surname>Au</surname><given-names>HKE</given-names></string-name>, <string-name name-style="western"><surname>Isalan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mielcarek</surname><given-names>M</given-names></string-name>. <article-title>Gene therapy advances: a meta&#8208;analysis of AAV usage in clinical settings</article-title>. <source>Front Med</source>. <year>2022</year>;<volume>8</volume>:<elocation-id>809118</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fmed.2021.809118</pub-id><pub-id pub-id-type="pmcid">PMC8864161</pub-id><pub-id pub-id-type="pmid">35223884</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jimd12697-cit-0032"><string-name name-style="western"><surname>Byrne</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Falk</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Cl&#233;ment</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Mah</surname><given-names>CS</given-names></string-name>. <article-title>Gene therapy approaches for lysosomal storage disease: next&#8208;generation treatment</article-title>. <source>Hum Gene Ther</source>. <year>2012</year>;<volume>23</volume>(<issue>8</issue>):<fpage>808</fpage>&#8208;<lpage>815</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2012.140</pub-id><pub-id pub-id-type="pmid">22794786</pub-id><pub-id pub-id-type="pmcid">PMC3413894</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jimd12697-cit-0033"><string-name name-style="western"><surname>Guilbaud</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Devaux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Couzini&#233;</surname><given-names>C</given-names></string-name>, et al. <article-title>Five years of successful inducible transgene expression following locoregional adeno&#8208;associated virus delivery in nonhuman primates with no detectable immunity</article-title>. <source>Hum Gene Ther</source>. <year>2019</year>;<volume>30</volume>(<issue>7</issue>):<fpage>802</fpage>&#8208;<lpage>813</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2018.234</pub-id><pub-id pub-id-type="pmid">30808235</pub-id><pub-id pub-id-type="pmcid">PMC6648187</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jimd12697-cit-0034"><string-name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>O'Neill</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Maffei</surname><given-names>B</given-names></string-name>, et al. <article-title>On&#8208;demand cell&#8208;autonomous gene therapy for brain circuit disorders</article-title>. <source>Science</source>. <year>2022</year>;<volume>378</volume>(<issue>6619</issue>):<fpage>523</fpage>&#8208;<lpage>532</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abq6656</pub-id><pub-id pub-id-type="pmid">36378958</pub-id><pub-id pub-id-type="pmcid">PMC7613996</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jimd12697-cit-0035"><string-name name-style="western"><surname>Bohlen</surname><given-names>MO</given-names></string-name>, <string-name name-style="western"><surname>McCown</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Powell</surname><given-names>SK</given-names></string-name>, et al. <article-title>Adeno&#8208;associated virus capsid&#8208;promoter interactions in the brain translate from rat to the nonhuman primate</article-title>. <source>Hum Gene Ther</source>. <year>2020</year>;<volume>31</volume>(<issue>21&#8208;22</issue>):<fpage>1155</fpage>&#8208;<lpage>1168</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2020.196</pub-id><pub-id pub-id-type="pmid">32940068</pub-id><pub-id pub-id-type="pmcid">PMC7698875</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jimd12697-cit-0036"><string-name name-style="western"><surname>Powell</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Samulski</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>McCown</surname><given-names>TJ</given-names></string-name>. <article-title>AAV capsid&#8208;promoter interactions determine CNS cell&#8208;selective gene expression in vivo</article-title>. <source>Mol Ther</source>. <year>2020</year>;<volume>28</volume>(<issue>5</issue>):<fpage>1373</fpage>&#8208;<lpage>1380</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2020.03.007</pub-id><pub-id pub-id-type="pmid">32213322</pub-id><pub-id pub-id-type="pmcid">PMC7210720</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jimd12697-cit-0037"><string-name name-style="western"><surname>Powell</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Rivera&#8208;Soto</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>SJ</given-names></string-name>. <article-title>Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy</article-title>. <source>Discov Med</source>. <year>2015</year>;<volume>19</volume>(<issue>102</issue>):<fpage>49</fpage>&#8208;<lpage>57</lpage>.<pub-id pub-id-type="pmid">25636961</pub-id><pub-id pub-id-type="pmcid">PMC4505817</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jimd12697-cit-0038"><string-name name-style="western"><surname>Domenger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Grimm</surname><given-names>D</given-names></string-name>. <article-title>Next&#8208;generation AAV vectors&#8212;do not judge a virus (only) by its cover</article-title>. <source>Hum Mol Genet</source>. <year>2019</year>;<volume>28</volume>(<issue>R1</issue>):<fpage>R3</fpage>&#8208;<lpage>R14</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddz148</pub-id><pub-id pub-id-type="pmid">31261383</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jimd12697-cit-0039"><string-name name-style="western"><surname>Sinnett</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Boyle</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lyons</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>SJ</given-names></string-name>. <article-title>Engineered microRNA&#8208;based regulatory element permits safe high&#8208;dose mini<italic toggle="yes">MECP2</italic> gene therapy in Rett mice</article-title>. <source>Brain</source>. <year>2021</year>;<volume>144</volume>(<issue>10</issue>):<fpage>3005</fpage>&#8208;<lpage>3019</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awab182</pub-id><pub-id pub-id-type="pmid">33950254</pub-id><pub-id pub-id-type="pmcid">PMC8783608</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jimd12697-cit-0040"><string-name name-style="western"><surname>Samaranch</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Blits</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>San Sebastian</surname><given-names>W</given-names></string-name>, et al. <article-title>MR&#8208;guided parenchymal delivery of adeno&#8208;associated viral vector serotype 5 in non&#8208;human primate brain</article-title>. <source>Gene Ther</source>. <year>2017</year>;<volume>24</volume>(<issue>4</issue>):<fpage>253</fpage>&#8208;<lpage>261</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gt.2017.14</pub-id><pub-id pub-id-type="pmid">28300083</pub-id><pub-id pub-id-type="pmcid">PMC5404203</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jimd12697-cit-0041"><string-name name-style="western"><surname>Bailey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Rozenberg</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>SJ</given-names></string-name>. <article-title>Comparison of high&#8208;dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies</article-title>. <source>Brain Res</source>. <year>2020</year>;<volume>1739</volume>:<elocation-id>146832</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.brainres.2020.146832</pub-id><pub-id pub-id-type="pmid">32289279</pub-id><pub-id pub-id-type="pmcid">PMC7997047</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jimd12697-cit-0042"><string-name name-style="western"><surname>Chandran</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chowdhury</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Perkinton</surname><given-names>M</given-names></string-name>, et al. <article-title>Assessment of AAV9 distribution and transduction in rats after administration through intrastriatal, intracisterna magna and lumbar intrathecal routes</article-title>. <source>Gene Ther</source>. <year>2023</year>;<volume>30</volume>:<fpage>132</fpage>&#8208;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41434-022-00346-1</pub-id><pub-id pub-id-type="pmid">35637286</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jimd12697-cit-0043"><string-name name-style="western"><surname>Flotte</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Cataltepe</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Puri</surname><given-names>A</given-names></string-name>, et al. <article-title>AAV gene therapy for Tay&#8208;Sachs disease</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>2</issue>):<fpage>251</fpage>&#8208;<lpage>259</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-021-01664-4</pub-id><pub-id pub-id-type="pmid">35145305</pub-id><pub-id pub-id-type="pmcid">PMC10786171</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jimd12697-cit-0044"><string-name name-style="western"><surname>Armstrong</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Okun</surname><given-names>MS</given-names></string-name>. <article-title>Diagnosis and treatment of Parkinson disease: a review</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>6</issue>):<fpage>548</fpage>&#8208;<lpage>560</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2019.22360</pub-id><pub-id pub-id-type="pmid">32044947</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jimd12697-cit-0045"><string-name name-style="western"><surname>Merola</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Van Laar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lonser</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bankiewicz</surname><given-names>K</given-names></string-name>. <article-title>Gene therapy for Parkinson's disease: contemporary practice and emerging concepts</article-title>. <source>Expert Rev Neurother</source>. <year>2020</year>;<volume>20</volume>(<issue>6</issue>):<fpage>577</fpage>&#8208;<lpage>590</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14737175.2020.1763794</pub-id><pub-id pub-id-type="pmid">32425079</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jimd12697-cit-0046"><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barral</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Waddington</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>. <article-title>Gene therapy for dopamine dyshomeostasis: from Parkinson's to primary neurotransmitter diseases</article-title>. <source>Mov Disord</source>. <year>2023</year>;<volume>38</volume>:<fpage>924</fpage>&#8208;<lpage>936</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.29416</pub-id><pub-id pub-id-type="pmid">37147851</pub-id><pub-id pub-id-type="pmcid">PMC10946997</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jimd12697-cit-0047"><string-name name-style="western"><surname>Eberling</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Jagust</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, et al. <article-title>Results from a phase I safety trial of <italic toggle="yes">hAADC</italic> gene therapy for Parkinson disease</article-title>. <source>Neurology</source>. <year>2008</year>;<volume>70</volume>(<issue>21</issue>):<fpage>1980</fpage>&#8208;<lpage>1983</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000312381.29287.ff</pub-id><pub-id pub-id-type="pmid">18401019</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jimd12697-cit-0048"><string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Starr</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Larson</surname><given-names>PS</given-names></string-name>, et al. <article-title>Safety and tolerability of putaminal <italic toggle="yes">AADC</italic> gene therapy for Parkinson disease</article-title>. <source>Neurology</source>. <year>2009</year>;<volume>73</volume>(<issue>20</issue>):<fpage>1662</fpage>&#8208;<lpage>1669</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181c29356</pub-id><pub-id pub-id-type="pmid">19828868</pub-id><pub-id pub-id-type="pmcid">PMC2839805</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jimd12697-cit-0049"><string-name name-style="western"><surname>Mittermeyer</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Rosenbluth</surname><given-names>KH</given-names></string-name>, et al. <article-title>Long&#8208;term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease</article-title>. <source>Hum Gene Ther</source>. <year>2012</year>;<volume>23</volume>(<issue>4</issue>):<fpage>377</fpage>&#8208;<lpage>381</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2011.220</pub-id><pub-id pub-id-type="pmid">22424171</pub-id><pub-id pub-id-type="pmcid">PMC4530392</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jimd12697-cit-0050"><string-name name-style="western"><surname>Muramatsu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fujimoto</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>S</given-names></string-name>, et al. <article-title>A phase I study of aromatic <sc>l</sc>&#8208;amino acid decarboxylase gene therapy for Parkinson's disease</article-title>. <source>Mol Ther</source>. <year>2010</year>;<volume>18</volume>(<issue>9</issue>):<fpage>1731</fpage>&#8208;<lpage>1735</lpage>. doi:<pub-id pub-id-type="doi">10.1038/mt.2010.135</pub-id><pub-id pub-id-type="pmid">20606642</pub-id><pub-id pub-id-type="pmcid">PMC2956925</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jimd12697-cit-0051"><string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Bankiewicz</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Van Laar</surname><given-names>AD</given-names></string-name>, et al. <article-title>Magnetic resonance imaging&#8208;guided phase 1 trial of putaminal <italic toggle="yes">AADC</italic> gene therapy for Parkinson's disease</article-title>. <source>Ann Neurol</source>. <year>2019</year>;<volume>85</volume>(<issue>5</issue>):<fpage>704</fpage>&#8208;<lpage>714</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25450</pub-id><pub-id pub-id-type="pmid">30802998</pub-id><pub-id pub-id-type="pmcid">PMC6593762</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jimd12697-cit-0052"><string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Richardson</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Laar</surname><given-names>ADV</given-names></string-name>, et al. <article-title>Safety of AADC gene therapy for moderately advanced Parkinson disease: three&#8208;year outcomes from the PD&#8208;1101 trial</article-title>. <source>Neurology</source>. <year>2022</year>;<volume>98</volume>(<issue>1</issue>):<fpage>e40</fpage>&#8208;<lpage>e50</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000012952</pub-id><pub-id pub-id-type="pmid">34649873</pub-id><pub-id pub-id-type="pmcid">PMC8726573</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jimd12697-cit-0053"><string-name name-style="western"><surname>Palfi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gurruchaga</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Ralph</surname><given-names>GS</given-names></string-name>, et al. <article-title>Long&#8208;term safety and tolerability of ProSavin, a Lentiviral vector&#8208;based gene therapy for Parkinson's disease: a dose escalation, open&#8208;label, phase 1/2 trial</article-title>. <source>Lancet</source>. <year>2014</year>;<volume>383</volume>(<issue>9923</issue>):<fpage>1138</fpage>&#8208;<lpage>1146</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(13)61939-X</pub-id><pub-id pub-id-type="pmid">24412048</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jimd12697-cit-0054"><string-name name-style="western"><surname>Palfi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gurruchaga</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lepetit</surname><given-names>H</given-names></string-name>, et al. <article-title>Long&#8208;term follow&#8208;up of a phase I/II study of ProSavin, a lentiviral vector gene therapy for Parkinson's disease</article-title>. <source>Hum Gene Ther Clin Dev</source>. <year>2018</year>;<volume>29</volume>(<issue>3</issue>):<fpage>148</fpage>&#8208;<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1089/humc.2018.081</pub-id><pub-id pub-id-type="pmid">30156440</pub-id><pub-id pub-id-type="pmcid">PMC6157351</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jimd12697-cit-0055"><string-name name-style="western"><surname>Kaplitt</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Feigin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>C</given-names></string-name>, et al. <article-title>Safety and tolerability of gene therapy with an adeno&#8208;associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial</article-title>. <source>Lancet</source>. <year>2007</year>;<volume>369</volume>(<issue>9579</issue>):<fpage>2097</fpage>&#8208;<lpage>2105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60982-9</pub-id><pub-id pub-id-type="pmid">17586305</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jimd12697-cit-0056"><string-name name-style="western"><surname>LeWitt</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Rezai</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Leehey</surname><given-names>MA</given-names></string-name>, et al. <article-title>AAV2&#8208;<italic toggle="yes">GAD</italic> gene therapy for advanced Parkinson's disease: a double&#8208;blind, sham&#8208;surgery controlled, randomised trial</article-title>. <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>309</fpage>&#8208;<lpage>319</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(11)70039-4</pub-id><pub-id pub-id-type="pmid">21419704</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jimd12697-cit-0057"><string-name name-style="western"><surname>Niethammer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>LeWitt</surname><given-names>PA</given-names></string-name>, et al. <article-title>Long&#8208;term follow&#8208;up of a randomized AAV2&#8208;<italic toggle="yes">GAD</italic> gene therapy trial for Parkinson's disease</article-title>. <source>JCI Insight</source>. <year>2017</year>;<volume>2</volume>(<issue>7</issue>):<elocation-id>e90133</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.90133</pub-id><pub-id pub-id-type="pmid">28405611</pub-id><pub-id pub-id-type="pmcid">PMC5374069</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="jimd12697-cit-0058"><string-name name-style="western"><surname>Richardson</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Bankiewicz</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Christine</surname><given-names>CW</given-names></string-name>, et al. <article-title>Data&#8208;driven evolution of neurosurgical gene therapy delivery in Parkinson's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2020</year>;<volume>91</volume>(<issue>11</issue>):<fpage>1210</fpage>&#8208;<lpage>1218</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2020-322904</pub-id><pub-id pub-id-type="pmid">32732384</pub-id><pub-id pub-id-type="pmcid">PMC7569395</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0059"><label>59</label><mixed-citation publication-type="book" id="jimd12697-cit-0059"><collab collab-type="authors">Voyager Therapeutics Inc</collab>
. <source>Voyager Therapeutics Provides Update on NBIb&#8208;1817 (VY&#8208;AADC) Gene Therapy Program</source>. GlobeNewswire; <year>2021</year>. Accessed September 25, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ir.voyagertherapeutics.com/news-releases/news-release-details/voyager-therapeutics-provides-update-nbib-1817-vy-aadc-gene-0/" ext-link-type="uri">https://ir.voyagertherapeutics.com/news&#8208;releases/news&#8208;release&#8208;details/voyager&#8208;therapeutics&#8208;provides&#8208;update&#8208;nbib&#8208;1817&#8208;vy&#8208;aadc&#8208;gene&#8208;0/</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="jimd12697-cit-0060"><string-name name-style="western"><surname>Rotstein</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>UJ</given-names></string-name>. <article-title>Consideration of gene therapy for paediatric neurotransmitter diseases</article-title>. <source>J Inherit Metab Dis</source>. <year>2009</year>;<volume>32</volume>(<issue>3</issue>):<fpage>387</fpage>&#8208;<lpage>394</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10545-009-1054-7</pub-id><pub-id pub-id-type="pmid">19259783</pub-id><pub-id pub-id-type="pmcid">PMC4848069</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="jimd12697-cit-0061"><string-name name-style="western"><surname>Brun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ngu</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Keng</surname><given-names>WT</given-names></string-name>, et al. <article-title>Clinical and biochemical features of aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Neurology</source>. <year>2010</year>;<volume>75</volume>(<issue>1</issue>):<fpage>64</fpage>&#8208;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181e620ae</pub-id><pub-id pub-id-type="pmid">20505134</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="jimd12697-cit-0062"><string-name name-style="western"><surname>Pearson</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Gilbert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Opladen</surname><given-names>T</given-names></string-name>, et al. <article-title>AADC deficiency from infancy to adulthood: symptoms and developmental outcome in an international cohort of 63 patients</article-title>. <source>J Inherit Metab Dis</source>. <year>2020</year>;<volume>43</volume>(<issue>5</issue>):<fpage>1121</fpage>&#8208;<lpage>1130</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12247</pub-id><pub-id pub-id-type="pmid">32369189</pub-id><pub-id pub-id-type="pmcid">PMC7540529</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="jimd12697-cit-0063"><string-name name-style="western"><surname>Lee</surname><given-names>W&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Weng</surname><given-names>W&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>SS&#8208;F</given-names></string-name>. <article-title>Microstructural changes of brain in patients with aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Hum Brain Mapp</source>. <year>2017</year>;<volume>38</volume>(<issue>3</issue>):<fpage>1532</fpage>&#8208;<lpage>1540</lpage>. doi:<pub-id pub-id-type="doi">10.1002/hbm.23470</pub-id><pub-id pub-id-type="pmid">27859928</pub-id><pub-id pub-id-type="pmcid">PMC6867156</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="jimd12697-cit-0064"><string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Hwu</surname><given-names>W&#8208;L</given-names></string-name>. <article-title>A review of aromatic <sc>l</sc>&#8208;amino acid decarboxylase (AADC) deficiency in Taiwan</article-title>. <source>Am J Med Genet C Semin Med Genet</source>. <year>2019</year>;<volume>181</volume>(<issue>2</issue>):<fpage>226</fpage>&#8208;<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ajmg.c.31670</pub-id><pub-id pub-id-type="pmid">30614627</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0065"><label>65</label><mixed-citation publication-type="book" id="jimd12697-cit-0065"><collab collab-type="authors">European Medicines Agency</collab>
. <source>Upstaza&#8212;Assessment Report</source>. European Medicines Agency; <year>2022</year>. Accessed September 30, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/assessment-report/upstaza-epar-public-assessment-report_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/assessment-report/upstaza-epar-public-assessment-report_en.pdf</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="jimd12697-cit-0066"><string-name name-style="western"><surname>Hwu</surname><given-names>PW&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Kiening</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Anselm</surname><given-names>I</given-names></string-name>, et al. <article-title>Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease</article-title>. <source>EMBO Mol Med</source>. <year>2021</year>;<volume>13</volume>(<issue>9</issue>):<elocation-id>e14712</elocation-id>. doi:<pub-id pub-id-type="doi">10.15252/emmm.202114712</pub-id><pub-id pub-id-type="pmid">34423905</pub-id><pub-id pub-id-type="pmcid">PMC8422070</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="jimd12697-cit-0067"><string-name name-style="western"><surname>Hwu</surname><given-names>W&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Muramatsu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>S&#8208;H</given-names></string-name>, et al. <article-title>Gene therapy for aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>(<issue>134</issue>):<elocation-id>134ra61</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3003640</pub-id><pub-id pub-id-type="pmid">22593174</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="jimd12697-cit-0068"><string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>S&#8208;H</given-names></string-name>, et al. <article-title>Efficacy and safety of AAV2 gene therapy in children with aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency: an open&#8208;label, phase 1/2 trial</article-title>. <source>Lancet Child Adolesc Health</source>. <year>2017</year>;<volume>1</volume>(<issue>4</issue>):<fpage>265</fpage>&#8208;<lpage>273</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2352-4642(17)30125-6</pub-id><pub-id pub-id-type="pmid">30169182</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="jimd12697-cit-0069"><string-name name-style="western"><surname>Tai</surname><given-names>C&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, et al. <article-title>Long&#8208;term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency</article-title>. <source>Mol Ther</source>. <year>2022</year>;<volume>30</volume>(<issue>2</issue>):<fpage>509</fpage>&#8208;<lpage>518</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2021.11.005</pub-id><pub-id pub-id-type="pmid">34763085</pub-id><pub-id pub-id-type="pmcid">PMC8822132</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="jimd12697-cit-0070"><string-name name-style="western"><surname>Hwu</surname><given-names>PW&#8208;L</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, et al. <article-title>390 Efficacy of gene therapy with eladocagene exuparvovec in patients with AADC deficiency compared with natural history controls</article-title>. <source>Arch Dis Child</source>. <year>2021</year>;<volume>106</volume>(<issue>suppl 2</issue>):<fpage>A163</fpage>&#8208;<lpage>A164</lpage>. doi:<pub-id pub-id-type="doi">10.1136/archdischild-2021-europaediatrics.390</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="jimd12697-cit-0071"><string-name name-style="western"><surname>Tseng</surname><given-names>C&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, et al. <article-title>Gene therapy improves brain white matter in aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Ann Neurol</source>. <year>2019</year>;<volume>85</volume>(<issue>5</issue>):<fpage>644</fpage>&#8208;<lpage>652</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.25467</pub-id><pub-id pub-id-type="pmid">30864153</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="jimd12697-cit-0072"><string-name name-style="western"><surname>Fran&#231;ois&#8208;Heude</surname><given-names>M&#8208;C</given-names></string-name>, <string-name name-style="western"><surname>Poulen</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Flamand Roze</surname><given-names>E</given-names></string-name>, et al. <article-title>Intraputaminal gene delivery in two patients with aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Mov Disord Clin Pract</source>. <year>2023</year>;<volume>10</volume>(<issue>5</issue>):<fpage>811</fpage>&#8208;<lpage>818</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mdc3.13685</pub-id><pub-id pub-id-type="pmid">37205256</pub-id><pub-id pub-id-type="pmcid">PMC10187009</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="jimd12697-cit-0073"><string-name name-style="western"><surname>Kojima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Nakajima</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Taga</surname><given-names>N</given-names></string-name>, et al. <article-title>Gene therapy improves motor and mental function of aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Brain</source>. <year>2019</year>;<volume>142</volume>(<issue>2</issue>):<fpage>322</fpage>&#8208;<lpage>333</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awy331</pub-id><pub-id pub-id-type="pmid">30689738</pub-id><pub-id pub-id-type="pmcid">PMC6377184</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="jimd12697-cit-0074"><string-name name-style="western"><surname>Onuki</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Ono</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nakajima</surname><given-names>T</given-names></string-name>, et al. <article-title>Dopaminergic restoration of prefrontal cortico&#8208;putaminal network in gene therapy for aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Brain Commun</source>. <year>2021</year>;<volume>3</volume>:<elocation-id>fcab078</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcab078</pub-id><pub-id pub-id-type="pmid">34423296</pub-id><pub-id pub-id-type="pmcid">PMC8374966</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="jimd12697-cit-0075"><string-name name-style="western"><surname>Hashiguchi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kojima</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tadahiro</surname><given-names>M</given-names></string-name>, et al. <article-title>Long&#8208;term efficacy of gene therapy for AADC deficiency, including patients with a moderate phenotype</article-title>. <source>Mol Ther</source>. <year>2023</year>;<volume>31</volume>:<elocation-id>S91</elocation-id>.</mixed-citation></ref><ref id="jimd12697-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="jimd12697-cit-0076"><string-name name-style="western"><surname>Caine</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Shohat</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>J&#8208;K</given-names></string-name>, et al. <article-title>A pathogenic S250F missense mutation results in a mouse model of mild aromatic <sc>l</sc>&#8208;amino acid decarboxylase (AADC) deficiency</article-title>. <source>Hum Mol Genet</source>. <year>2017</year>;<volume>26</volume>(<issue>22</issue>):<fpage>4406</fpage>&#8208;<lpage>4415</lpage>. doi:<pub-id pub-id-type="doi">10.1093/hmg/ddx326</pub-id><pub-id pub-id-type="pmid">28973165</pub-id><pub-id pub-id-type="pmcid">PMC5886209</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="jimd12697-cit-0077"><string-name name-style="western"><surname>Pearson</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>San Sebastian</surname><given-names>W</given-names></string-name>, et al. <article-title>Gene therapy for aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency by MR&#8208;guided direct delivery of AAV2&#8208;AADC to midbrain dopaminergic neurons</article-title>. <source>Nat Commun</source>. <year>2021</year>;<volume>12</volume>(<issue>1</issue>):<elocation-id>4251</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41467-021-24524-8</pub-id><pub-id pub-id-type="pmid">34253733</pub-id><pub-id pub-id-type="pmcid">PMC8275582</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="jimd12697-cit-0078"><string-name name-style="western"><surname>Bankiewicz</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kohutnicka</surname><given-names>M</given-names></string-name>, et al. <article-title>Midbrain gene therapy for AADC deficiency</article-title>. <source>Mol Ther</source>. <year>2023</year>;<volume>31</volume>:<elocation-id>S4</elocation-id>.</mixed-citation></ref><ref id="jimd12697-bib-0079"><label>79</label><mixed-citation publication-type="miscellaneous" id="jimd12697-cit-0079"><string-name name-style="western"><surname>Bankiewicz</surname><given-names>K</given-names></string-name>. <article-title>Study Protocol and Statistical Analysis Plan. Single&#8208;Stage, Open&#8208;Label, Safety and Efficacy Study of Adeno&#8208;Associated Virus Encoding Human Aromatic <sc>l</sc>&#8208;Amino Acid Decarboxylase by Magnetic Resonance MR&#8208;Guided Infusion into Midbrain in Pediatric Patients with AADC Deficiency</article-title>. Accessed April 30, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ProvidedDocs/13/NCT02852213/Prot_SAP_002.pdf" ext-link-type="uri">https://clinicaltrials.gov/ProvidedDocs/13/NCT02852213/Prot_SAP_002.pdf</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0080"><label>80</label><mixed-citation publication-type="miscellaneous" id="jimd12697-cit-0080"><collab collab-type="authors">Shanghai Vitalgen BioPharma Co., Ltd</collab>
. <article-title>Launch of an Investigator&#8208;Initiated Trial of VGN&#8208;R09b for Treating Aromatic L&#8208;Amino Acid Decarboxylase Deficiency (AADCD)</article-title>. Accessed May 23, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.vitalgen-biomed.com/en/details.php?id=15" ext-link-type="uri">http://www.vitalgen-biomed.com/en/details.php?id=15</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="jimd12697-cit-0081"><string-name name-style="western"><surname>Tsai</surname><given-names>C&#8208;R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>H&#8208;F</given-names></string-name>, <string-name name-style="western"><surname>Chi</surname><given-names>C&#8208;S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M&#8208;T</given-names></string-name>, <string-name name-style="western"><surname>Hsu</surname><given-names>C&#8208;C</given-names></string-name>. <article-title>Antisense oligonucleotides modulate dopa decarboxylase function in aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency</article-title>. <source>Hum Mutat</source>. <year>2018</year>;<volume>39</volume>(<issue>12</issue>):<fpage>2072</fpage>&#8208;<lpage>2082</lpage>. doi:<pub-id pub-id-type="doi">10.1002/humu.23659</pub-id><pub-id pub-id-type="pmid">30260058</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="jimd12697-cit-0082"><string-name name-style="western"><surname>Roberts</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Langer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>MJA</given-names></string-name>. <article-title>Advances in oligonucleotide drug delivery</article-title>. <source>Nat Rev Drug Discov</source>. <year>2020</year>;<volume>19</volume>(<issue>10</issue>):<fpage>673</fpage>&#8208;<lpage>694</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41573-020-0075-7</pub-id><pub-id pub-id-type="pmid">32782413</pub-id><pub-id pub-id-type="pmcid">PMC7419031</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="jimd12697-cit-0083"><string-name name-style="western"><surname>Kuijper</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Bergsma</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Pijnappel</surname><given-names>WWMP</given-names></string-name>, <string-name name-style="western"><surname>Aartsma&#8208;Rus</surname><given-names>A</given-names></string-name>. <article-title>Opportunities and challenges for antisense oligonucleotide therapies</article-title>. <source>J Inherit Metab Dis</source>. <year>2021</year>;<volume>44</volume>(<issue>1</issue>):<fpage>72</fpage>&#8208;<lpage>87</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12251</pub-id><pub-id pub-id-type="pmid">32391605</pub-id><pub-id pub-id-type="pmcid">PMC7891411</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="jimd12697-cit-0084"><string-name name-style="western"><surname>Kim</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>J</given-names></string-name>. <article-title>Tetrahydrobiopterin in energy metabolism and metabolic diseases</article-title>. <source>Pharmacol Res</source>. <year>2020</year>;<volume>157</volume>:<elocation-id>104827</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2020.104827</pub-id><pub-id pub-id-type="pmid">32348841</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="jimd12697-cit-0085"><string-name name-style="western"><surname>Leuzzi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Carducci</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Carducci</surname><given-names>C</given-names></string-name>, et al. <article-title>Phenotypic variability, neurological outcome and genetics background of 6&#8208;pyruvoyl&#8208;tetrahydropterin synthase deficiency</article-title>. <source>Clin Genet</source>. <year>2010</year>;<volume>77</volume>(<issue>3</issue>):<fpage>249</fpage>&#8208;<lpage>257</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1399-0004.2009.01306.x</pub-id><pub-id pub-id-type="pmid">20059486</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="jimd12697-cit-0086"><string-name name-style="western"><surname>Himmelreich</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Blau</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Th&#246;ny</surname><given-names>B</given-names></string-name>. <article-title>Molecular and metabolic bases of tetrahydrobiopterin (BH<sub>4</sub>) deficiencies</article-title>. <source>Mol Genet Metab</source>. <year>2021</year>;<volume>133</volume>(<issue>2</issue>):<fpage>123</fpage>&#8208;<lpage>136</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2021.04.003</pub-id><pub-id pub-id-type="pmid">33903016</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="jimd12697-cit-0087"><string-name name-style="western"><surname>Muniz</surname><given-names>JRC</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>NW</given-names></string-name>, <string-name name-style="western"><surname>Frise</surname><given-names>R</given-names></string-name>, et al. <article-title>Role of protein structure in variant annotation: structural insight of mutations causing 6&#8208;pyruvoyl&#8208;tetrahydropterin synthase deficiency</article-title>. <source>Pathology</source>. <year>2019</year>;<volume>51</volume>(<issue>3</issue>):<fpage>274</fpage>&#8208;<lpage>280</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pathol.2018.11.011</pub-id><pub-id pub-id-type="pmid">30853107</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="jimd12697-cit-0088"><string-name name-style="western"><surname>Th&#246;ny</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Leimbacher</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stuhlmann</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Heizmann</surname><given-names>CW</given-names></string-name>, <string-name name-style="western"><surname>Blau</surname><given-names>N</given-names></string-name>. <article-title>Retrovirus&#8208;mediated gene transfer of 6&#8208;pyruvoyl&#8208;tetrahydropterin synthase corrects tetrahydrobiopterin deficiency in fibroblasts from Hyperphenylalaninemic patients</article-title>. <source>Hum Gene Ther</source>. <year>1996</year>;<volume>7</volume>(<issue>13</issue>):<fpage>1587</fpage>&#8208;<lpage>1593</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.1996.7.13-1587</pub-id><pub-id pub-id-type="pmid">8864759</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="jimd12697-cit-0089"><string-name name-style="western"><surname>Kotterman</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Chalberg</surname><given-names>TW</given-names></string-name>, <string-name name-style="western"><surname>Schaffer</surname><given-names>DV</given-names></string-name>. <article-title>Viral vectors for gene therapy: translational and clinical outlook</article-title>. <source>Annu Rev Biomed Eng</source>. <year>2015</year>;<volume>17</volume>(<issue>1</issue>):<fpage>63</fpage>&#8208;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-bioeng-071813-104938</pub-id><pub-id pub-id-type="pmid">26643018</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="jimd12697-cit-0090"><string-name name-style="western"><surname>Abramowicz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gos</surname><given-names>M</given-names></string-name>. <article-title>Splicing mutations in human genetic disorders: examples, detection, and confirmation</article-title>. <source>J Appl Genet</source>. <year>2018</year>;<volume>59</volume>(<issue>3</issue>):<fpage>253</fpage>&#8208;<lpage>268</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13353-018-0444-7</pub-id><pub-id pub-id-type="pmid">29680930</pub-id><pub-id pub-id-type="pmcid">PMC6060985</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="jimd12697-cit-0091"><string-name name-style="western"><surname>Brasil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Viecelli</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Meili</surname><given-names>D</given-names></string-name>, et al. <article-title>Pseudoexon exclusion by antisense therapy in 6&#8208;pyruvoyl&#8208;tetrahydropterin synthase deficiency</article-title>. <source>Hum Mutat</source>. <year>2011</year>;<volume>32</volume>(<issue>9</issue>):<fpage>1019</fpage>&#8208;<lpage>1027</lpage>. doi:<pub-id pub-id-type="doi">10.1002/humu.21529</pub-id><pub-id pub-id-type="pmid">21542064</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="jimd12697-cit-0092"><string-name name-style="western"><surname>Mart&#237;nez&#8208;Pizarro</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Leal</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Holm</surname><given-names>LL</given-names></string-name>, et al. <article-title>Antisense oligonucleotide rescue of deep&#8208;intronic variants activating pseudoexons in the 6&#8208;pyruvoyl&#8208;tetrahydropterin synthase gene</article-title>. <source>Nucleic Acid Ther</source>. <year>2022</year>;<volume>32</volume>(<issue>5</issue>):<fpage>378</fpage>&#8208;<lpage>390</lpage>. doi:<pub-id pub-id-type="doi">10.1089/nat.2021.0066</pub-id><pub-id pub-id-type="pmid">35833796</pub-id><pub-id pub-id-type="pmcid">PMC9595628</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="jimd12697-cit-0093"><string-name name-style="western"><surname>Meili</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kralovicova</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zagalak</surname><given-names>J</given-names></string-name>, et al. <article-title>Disease&#8208;causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE&#8208;2 and antisense <italic toggle="yes">Alu</italic> lacking the poly(T)&#8208;tail</article-title>. <source>Hum Mutat</source>. <year>2009</year>;<volume>30</volume>(<issue>5</issue>):<fpage>823</fpage>&#8208;<lpage>831</lpage>. doi:<pub-id pub-id-type="doi">10.1002/humu.20969</pub-id><pub-id pub-id-type="pmid">19280650</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="jimd12697-cit-0094"><string-name name-style="western"><surname>Bu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Farrer</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Khoshbouei</surname><given-names>H</given-names></string-name>. <article-title>Dynamic control of the dopamine transporter in neurotransmission and homeostasis</article-title>. <source>npj Parkinsons Dis</source>. <year>2021</year>;<volume>7</volume>:<elocation-id>22</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41531-021-00161-2</pub-id><pub-id pub-id-type="pmid">33674612</pub-id><pub-id pub-id-type="pmcid">PMC7935902</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="jimd12697-cit-0095"><string-name name-style="western"><surname>Kristensen</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>J&#248;rgensen</surname><given-names>TN</given-names></string-name>, et al. <article-title>SLC6 neurotransmitter transporters: structure, function, and regulation</article-title>. <source>Pharmacol Rev</source>. <year>2011</year>;<volume>63</volume>(<issue>3</issue>):<fpage>585</fpage>&#8208;<lpage>640</lpage>. doi:<pub-id pub-id-type="doi">10.1124/pr.108.000869</pub-id><pub-id pub-id-type="pmid">21752877</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="jimd12697-cit-0096"><string-name name-style="western"><surname>Pramod</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Foster</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Carvelli</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Henry</surname><given-names>LK</given-names></string-name>. <article-title>SLC6 transporters: structure, function, regulation, disease association and therapeutics</article-title>. <source>Mol Aspects Med</source>. <year>2013</year>;<volume>34</volume>(<issue>2</issue>):<fpage>197</fpage>&#8208;<lpage>219</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mam.2012.07.002</pub-id><pub-id pub-id-type="pmid">23506866</pub-id><pub-id pub-id-type="pmcid">PMC3602807</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="jimd12697-cit-0097"><string-name name-style="western"><surname>Mazei&#8208;Robison</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Couch</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Shelton</surname><given-names>RC</given-names></string-name>, <string-name name-style="western"><surname>Stein</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Blakely</surname><given-names>RD</given-names></string-name>. <article-title>Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder</article-title>. <source>Neuropharmacology</source>. <year>2005</year>;<volume>49</volume>(<issue>6</issue>):<fpage>724</fpage>&#8208;<lpage>736</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuropharm.2005.08.003</pub-id><pub-id pub-id-type="pmid">16171832</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="jimd12697-cit-0098"><string-name name-style="western"><surname>DiCarlo</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Aguilar</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Matthies</surname><given-names>HJG</given-names></string-name>, et al. <article-title>Autism&#8208;linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine&#8208;dependent behaviors</article-title>. <source>J Clin Invest</source>. <year>2020</year>;<volume>129</volume>(<issue>8</issue>):<fpage>3407</fpage>&#8208;<lpage>3419</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI127411</pub-id><pub-id pub-id-type="pmcid">PMC6668686</pub-id><pub-id pub-id-type="pmid">31094705</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="jimd12697-cit-0099"><string-name name-style="western"><surname>Reith</surname><given-names>MEA</given-names></string-name>, <string-name name-style="western"><surname>Kortagere</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wiers</surname><given-names>CE</given-names></string-name>, et al. <article-title>The dopamine transporter gene <italic toggle="yes">SLC6A3</italic>: multidisease risks</article-title>. <source>Mol Psychiatry</source>. <year>2022</year>;<volume>27</volume>(<issue>2</issue>):<fpage>1031</fpage>&#8208;<lpage>1046</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41380-021-01341-5</pub-id><pub-id pub-id-type="pmid">34650206</pub-id><pub-id pub-id-type="pmcid">PMC9008071</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="jimd12697-cit-0100"><string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>S&#8208;Y</given-names></string-name>, et al. <article-title>Homozygous loss&#8208;of&#8208;function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism&#8208;dystonia</article-title>. <source>J Clin Invest</source>. <year>2009</year>;<volume>119</volume>(<issue>6</issue>):<fpage>1595</fpage>&#8208;<lpage>1603</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI39060</pub-id><pub-id pub-id-type="pmid">19478460</pub-id><pub-id pub-id-type="pmcid">PMC2689114</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="jimd12697-cit-0101"><string-name name-style="western"><surname>Kurian</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhen</surname><given-names>J</given-names></string-name>, et al. <article-title>Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study</article-title>. <source>Lancet Neurol</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>54</fpage>&#8208;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(10)70269-6</pub-id><pub-id pub-id-type="pmid">21112253</pub-id><pub-id pub-id-type="pmcid">PMC3002401</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="jimd12697-cit-0102"><string-name name-style="western"><surname>Herborg</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jensen</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Tolstoy</surname><given-names>S</given-names></string-name>, et al. <article-title>Identifying dominant&#8208;negative actions of a dopamine transporter variant in patients with parkinsonism and neuropsychiatric disease</article-title>. <source>JCI Insight</source>. <year>2021</year>;<volume>6</volume>(<issue>18</issue>):<elocation-id>e151496</elocation-id>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.151496</pub-id><pub-id pub-id-type="pmid">34375312</pub-id><pub-id pub-id-type="pmcid">PMC8492322</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="jimd12697-cit-0103"><string-name name-style="western"><surname>Hansen</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Skj&#248;rringe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Yasmeen</surname><given-names>S</given-names></string-name>, et al. <article-title>Missense dopamine transporter mutations associate with adult parkinsonism and ADHD</article-title>. <source>J Clin Invest</source>. <year>2014</year>;<volume>124</volume>(<issue>7</issue>):<fpage>3107</fpage>&#8208;<lpage>3120</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI73778</pub-id><pub-id pub-id-type="pmid">24911152</pub-id><pub-id pub-id-type="pmcid">PMC4071392</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="jimd12697-cit-0104"><string-name name-style="western"><surname>Sutton</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>EQ</given-names></string-name>, <string-name name-style="western"><surname>Homsi</surname><given-names>H</given-names></string-name>, et al. <article-title>Structure&#8208;activity relationships of dopamine transporter pharmacological chaperones</article-title>. <source>Front Cell Neurosci</source>. <year>2022</year>;<volume>16</volume>:<elocation-id>832536</elocation-id>.<pub-id pub-id-type="pmid">35614973</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncel.2022.832536</pub-id><pub-id pub-id-type="pmcid">PMC9124866</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="jimd12697-cit-0105"><string-name name-style="western"><surname>Giros</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jaber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Wightman</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>MG</given-names></string-name>. <article-title>Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter</article-title>. <source>Nature</source>. <year>1996</year>;<volume>379</volume>(<issue>6566</issue>):<fpage>606</fpage>&#8208;<lpage>612</lpage>. doi:<pub-id pub-id-type="doi">10.1038/379606a0</pub-id><pub-id pub-id-type="pmid">8628395</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="jimd12697-cit-0106"><string-name name-style="western"><surname>Jones</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Gainetdinov</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Jaber</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Giros</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wightman</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Caron</surname><given-names>MG</given-names></string-name>. <article-title>Profound neuronal plasticity in response to inactivation of the dopamine transporter</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1998</year>;<volume>95</volume>(<issue>7</issue>):<fpage>4029</fpage>&#8208;<lpage>4034</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.95.7.4029</pub-id><pub-id pub-id-type="pmid">9520487</pub-id><pub-id pub-id-type="pmcid">PMC19957</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="jimd12697-cit-0107"><string-name name-style="western"><surname>Cyr</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Beaulieu</surname><given-names>J&#8208;M</given-names></string-name>, <string-name name-style="western"><surname>Laakso</surname><given-names>A</given-names></string-name>, et al. <article-title>Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>(<issue>19</issue>):<fpage>11035</fpage>&#8208;<lpage>11040</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1831768100</pub-id><pub-id pub-id-type="pmid">12958210</pub-id><pub-id pub-id-type="pmcid">PMC196922</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="jimd12697-cit-0108"><string-name name-style="western"><surname>Schn&#252;tgen</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Doerflinger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Call&#233;ja</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wendling</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Chambon</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ghyselinck</surname><given-names>NB</given-names></string-name>. <article-title>A directional strategy for monitoring Cre&#8208;mediated recombination at the cellular level in the mouse</article-title>. <source>Nat Biotechnol</source>. <year>2003</year>;<volume>21</volume>(<issue>5</issue>):<fpage>562</fpage>&#8208;<lpage>565</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nbt811</pub-id><pub-id pub-id-type="pmid">12665802</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="jimd12697-cit-0109"><string-name name-style="western"><surname>Illiano</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bass</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Fichera</surname><given-names>L</given-names></string-name>, et al. <article-title>Recombinant adeno&#8208;associated virus&#8208;mediated rescue of function in a mouse model of dopamine transporter deficiency syndrome</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<elocation-id>46280</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/srep46280</pub-id><pub-id pub-id-type="pmid">28417953</pub-id><pub-id pub-id-type="pmcid">PMC5394687</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="jimd12697-cit-0110"><string-name name-style="western"><surname>Oh</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Hong</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Huh</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>K&#8208;S</given-names></string-name>. <article-title>Expression of transgenes in midbrain dopamine neurons using the tyrosine hydroxylase promoter</article-title>. <source>Gene Ther</source>. <year>2009</year>;<volume>16</volume>(<issue>3</issue>):<fpage>437</fpage>&#8208;<lpage>440</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gt.2008.148</pub-id><pub-id pub-id-type="pmid">18800154</pub-id><pub-id pub-id-type="pmcid">PMC2747767</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="jimd12697-cit-0111"><string-name name-style="western"><surname>Gompf</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Budygin</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Fuller</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Bass</surname><given-names>CE</given-names></string-name>. <article-title>Targeted genetic manipulations of neuronal subtypes using promoter&#8208;specific combinatorial AAVs in wild&#8208;type animals</article-title>. <source>Front Behav Neurosci</source>. <year>2015</year>;<volume>9</volume>:<elocation-id>152</elocation-id>.<pub-id pub-id-type="pmid">26190981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnbeh.2015.00152</pub-id><pub-id pub-id-type="pmcid">PMC4488755</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="jimd12697-cit-0112"><string-name name-style="western"><surname>Erben</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Welday</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Buonanno</surname><given-names>A</given-names></string-name>. <article-title>Toxic and phenotypic effects of AAV_Cre used to transduce mesencephalic dopaminergic neurons</article-title>. <source>Int J Mol Sci</source>. <year>2022</year>;<volume>23</volume>(<issue>16</issue>):<elocation-id>9462</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/ijms23169462</pub-id><pub-id pub-id-type="pmid">36012727</pub-id><pub-id pub-id-type="pmcid">PMC9408874</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="jimd12697-cit-0113"><string-name name-style="western"><surname>Ng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Barral</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>De La Fuente Barrigon</surname><given-names>C</given-names></string-name>, et al. <article-title>Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism</article-title>. <source>Sci Transl Med</source>. <year>2021</year>;<volume>13</volume>(<issue>594</issue>):<elocation-id>eaaw1564</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aaw1564</pub-id><pub-id pub-id-type="pmid">34011628</pub-id><pub-id pub-id-type="pmcid">PMC7612279</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0114"><label>114</label><mixed-citation publication-type="miscellaneous" id="jimd12697-cit-0114"><collab collab-type="authors">Bloomsbury Genetic Therapies</collab>
. <article-title>Bloomsbury Genetic Therapies Receives Rare Paediatric Disease Designation from the U.S. FDA for BGT&#8208;DTDS for the Treatment of Dopamine Transporter Deficiency Syndrome (DTDS)</article-title>. Accessed May 17, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://bloomsburygtx.com/bloomsbury-receives-rare-paediatric-disease-designation-from-the-u-s-fda-for-bgt-dtds-for-the-treatment-of-dopamine-transporter-deficiency-syndrome-dtds/" ext-link-type="uri">https://bloomsburygtx.com/bloomsbury-receives-rare-paediatric-disease-designation-from-the-u-s-fda-for-bgt-dtds-for-the-treatment-of-dopamine-transporter-deficiency-syndrome-dtds/</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="jimd12697-cit-0115"><string-name name-style="western"><surname>Carvill</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Schneider</surname><given-names>A</given-names></string-name>, et al. <article-title>Mutations in the GABA transporter <italic toggle="yes">SLC6A1</italic> cause epilepsy with myoclonic&#8208;atonic seizures</article-title>. <source>Am J Hum Genet</source>. <year>2015</year>;<volume>96</volume>(<issue>5</issue>):<fpage>808</fpage>&#8208;<lpage>815</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2015.02.016</pub-id><pub-id pub-id-type="pmid">25865495</pub-id><pub-id pub-id-type="pmcid">PMC4570550</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="jimd12697-cit-0116"><string-name name-style="western"><surname>Fattorini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Melone</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>F</given-names></string-name>. <article-title>A reappraisal of GAT&#8208;1 localization in neocortex</article-title>. <source>Front Cell Neurosci</source>. <year>2020</year>;<volume>14</volume>:<elocation-id>9</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fncel.2020.00009</pub-id><pub-id pub-id-type="pmid">32116556</pub-id><pub-id pub-id-type="pmcid">PMC7031676</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="jimd12697-cit-0117"><string-name name-style="western"><surname>Goodspeed</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez&#8208;Palma</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Iqbal</surname><given-names>S</given-names></string-name>, et al. <article-title>Current knowledge of SLC6A1&#8208;related neurodevelopmental disorders</article-title>. <source>Brain Commun</source>. <year>2020</year>;<volume>2</volume>(<issue>2</issue>):<elocation-id>fcaa170</elocation-id>. doi:<pub-id pub-id-type="doi">10.1093/braincomms/fcaa170</pub-id><pub-id pub-id-type="pmid">33241211</pub-id><pub-id pub-id-type="pmcid">PMC7677605</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="jimd12697-cit-0118"><string-name name-style="western"><surname>Kahen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kavus</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Geltzeiler</surname><given-names>A</given-names></string-name>, et al. <article-title>Neurodevelopmental phenotypes associated with pathogenic variants in <italic toggle="yes">SLC6A1</italic>
</article-title>. <source>J Med Genet</source>. <year>2022</year>;<volume>59</volume>(<issue>6</issue>):<fpage>536</fpage>&#8208;<lpage>543</lpage>. doi:<pub-id pub-id-type="doi">10.1136/jmedgenet-2021-107694</pub-id><pub-id pub-id-type="pmid">34006619</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="jimd12697-cit-0119"><string-name name-style="western"><surname>Mattison</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Butler</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Inglis</surname><given-names>GAS</given-names></string-name>, et al. <article-title>
<italic toggle="yes">SLC6A1</italic> variants identified in epilepsy patients reduce &#947;&#8208;aminobutyric acid transport</article-title>. <source>Epilepsia</source>. <year>2018</year>;<volume>59</volume>(<issue>9</issue>):<fpage>e135</fpage>&#8208;<lpage>e141</lpage>. doi:<pub-id pub-id-type="doi">10.1111/epi.14531</pub-id><pub-id pub-id-type="pmid">30132828</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="jimd12697-cit-0120"><string-name name-style="western"><surname>Cai</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Eissman</surname><given-names>J</given-names></string-name>, et al. <article-title>A missense mutation in <italic toggle="yes">SLC6A1</italic> associated with Lennox&#8208;Gastaut syndrome impairs GABA transporter 1 protein trafficking and function</article-title>. <source>Exp Neurol</source>. <year>2019</year>;<volume>320</volume>:<elocation-id>112973</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.expneurol.2019.112973</pub-id><pub-id pub-id-type="pmid">31176687</pub-id><pub-id pub-id-type="pmcid">PMC6849469</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="jimd12697-cit-0121"><string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>D</given-names></string-name>. <article-title>GABA receptors in brain development, function, and injury</article-title>. <source>Metab Brain Dis</source>. <year>2015</year>;<volume>30</volume>(<issue>2</issue>):<fpage>367</fpage>&#8208;<lpage>379</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-014-9560-1</pub-id><pub-id pub-id-type="pmid">24820774</pub-id><pub-id pub-id-type="pmcid">PMC4231020</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0122"><label>122</label><mixed-citation publication-type="miscellaneous" id="jimd12697-cit-0122"><collab collab-type="authors">Taysha Gene Therapies</collab>
. <article-title>Bringing New Cures to Life</article-title>. Accessed September 26, 2022. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ir.tayshagtx.com/node/7391/html" ext-link-type="uri">https://ir.tayshagtx.com/node/7391/html</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="jimd12697-cit-0123"><string-name name-style="western"><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Shaffo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rioux</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>SJ</given-names></string-name>. <article-title>Preclinical gene therapy with AAV9/SLC6A1 in a mouse model of SLC6A1 related disorder</article-title>. <source>Mol Ther</source>. <year>2022</year>;<volume>30</volume>(<issue>4</issue>):<elocation-id>80</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2022.04.017</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="jimd12697-cit-0124"><string-name name-style="western"><surname>Guo</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Rioux</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Shaffo</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>SJ</given-names></string-name>. <article-title>Developmental age effects for AAV9/SLC6A1 gene therapy in a mouse model of SLC6A1 related disorder</article-title>. <source>Mol Ther</source>. <year>2023</year>;<volume>31</volume>:<elocation-id>S344</elocation-id>.</mixed-citation></ref><ref id="jimd12697-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="jimd12697-cit-0125"><string-name name-style="western"><surname>Didiasova</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Banning</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brennenstuhl</surname><given-names>H</given-names></string-name>, et al. <article-title>Succinic semialdehyde dehydrogenase deficiency: an update</article-title>. <source>Cell</source>. <year>2020</year>;<volume>9</volume>(<issue>2</issue>):<elocation-id>477</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/cells9020477</pub-id><pub-id pub-id-type="pmcid">PMC7072817</pub-id><pub-id pub-id-type="pmid">32093054</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="jimd12697-cit-0126"><string-name name-style="western"><surname>Pearl</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Parviz</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Vogel</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Schreiber</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Theodore</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Gibson</surname><given-names>KM</given-names></string-name>. <article-title>Inherited disorders of gamma&#8208;aminobutyric acid metabolism and advances in <italic toggle="yes">ALDH5A1</italic> mutation identification</article-title>. <source>Dev Med Child Neurol</source>. <year>2015</year>;<volume>57</volume>(<issue>7</issue>):<fpage>611</fpage>&#8208;<lpage>617</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dmcn.12668</pub-id><pub-id pub-id-type="pmid">25558043</pub-id><pub-id pub-id-type="pmcid">PMC4485983</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="jimd12697-cit-0127"><string-name name-style="western"><surname>DiBacco</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Roullet</surname><given-names>J&#8208;B</given-names></string-name>, <string-name name-style="western"><surname>Kapur</surname><given-names>K</given-names></string-name>, et al. <article-title>Age&#8208;related phenotype and biomarker changes in SSADH deficiency</article-title>. <source>Ann Clin Transl Neurol</source>. <year>2019</year>;<volume>6</volume>(<issue>1</issue>):<fpage>114</fpage>&#8208;<lpage>120</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.696</pub-id><pub-id pub-id-type="pmid">30656189</pub-id><pub-id pub-id-type="pmcid">PMC6331944</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="jimd12697-cit-0128"><string-name name-style="western"><surname>Walters</surname><given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kirby</surname><given-names>T</given-names></string-name>, et al. <article-title>Postmortem analyses in a patient with succinic semialdehyde dehydrogenase deficiency (SSADHD): II. Histological, lipid, and gene expression outcomes in regional brain tissue</article-title>. <source>J Child Neurol</source>. <year>2021</year>;<volume>36</volume>(<issue>13&#8211;14</issue>):<fpage>1177</fpage>&#8208;<lpage>1188</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0883073820987742</pub-id><pub-id pub-id-type="pmid">33557678</pub-id><pub-id pub-id-type="pmcid">PMC8349921</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="jimd12697-cit-0129"><string-name name-style="western"><surname>Gupta</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jansen</surname><given-names>EEW</given-names></string-name>, <string-name name-style="western"><surname>Senephansiri</surname><given-names>H</given-names></string-name>, et al. <article-title>Liver&#8208;directed adenoviral gene transfer in murine succinate semialdehyde dehydrogenase deficiency</article-title>. <source>Mol Ther</source>. <year>2004</year>;<volume>9</volume>(<issue>4</issue>):<fpage>527</fpage>&#8208;<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2004.01.013</pub-id><pub-id pub-id-type="pmid">15093183</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="jimd12697-cit-0130"><string-name name-style="western"><surname>Gibson</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Jakobs</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Pearl</surname><given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Snead</surname><given-names>OC</given-names></string-name>. <article-title>Murine succinate semialdehyde dehydrogenase (SSADH) deficiency, a heritable disorder of GABA metabolism with epileptic phenotype</article-title>. <source>IUBMB Life</source>. <year>2005</year>;<volume>57</volume>(<issue>9</issue>):<fpage>639</fpage>&#8208;<lpage>644</lpage>. doi:<pub-id pub-id-type="doi">10.1080/15216540500264588</pub-id><pub-id pub-id-type="pmid">16203683</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="jimd12697-cit-0131"><string-name name-style="western"><surname>Kubaski</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Herbst</surname><given-names>ZM</given-names></string-name>, <string-name name-style="western"><surname>Pereira</surname><given-names>DAA</given-names></string-name>, et al. <article-title>Evaluation of 3&#8208;<italic toggle="yes">O</italic>&#8208;methyldopa as a biomarker for aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency in 7 Brazilian cases</article-title>. <source>Mol Genet Metab Rep</source>. <year>2021</year>;<volume>27</volume>:<elocation-id>100744</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgmr.2021.100744</pub-id><pub-id pub-id-type="pmid">33763332</pub-id><pub-id pub-id-type="pmcid">PMC7973244</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="jimd12697-cit-0132"><string-name name-style="western"><surname>Chien</surname><given-names>Y&#8208;H</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>P&#8208;W</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>N&#8208;C</given-names></string-name>, et al. <article-title>3&#8208;<italic toggle="yes">O</italic>&#8208;methyldopa levels in newborns: result of newborn screening for aromatic <sc>l</sc>&#8208;amino&#8208;acid decarboxylase deficiency</article-title>. <source>Mol Genet Metab</source>. <year>2016</year>;<volume>118</volume>(<issue>4</issue>):<fpage>259</fpage>&#8208;<lpage>263</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2016.05.011</pub-id><pub-id pub-id-type="pmid">27216367</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="jimd12697-cit-0133"><string-name name-style="western"><surname>Burlina</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Giuliani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Polo</surname><given-names>G</given-names></string-name>, et al. <article-title>Detection of 3&#8208;<italic toggle="yes">O</italic>&#8208;methyldopa in dried blood spots for neonatal diagnosis of aromatic <sc>l</sc>&#8208;amino&#8208;acid decarboxylase deficiency: the northeastern Italian experience</article-title>. <source>Mol Genet Metab</source>. <year>2021</year>;<volume>133</volume>(<issue>1</issue>):<fpage>56</fpage>&#8208;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymgme.2021.03.009</pub-id><pub-id pub-id-type="pmid">33744095</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="jimd12697-cit-0134"><string-name name-style="western"><surname>Brennenstuhl</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kohlm&#252;ller</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Gramer</surname><given-names>G</given-names></string-name>, et al. <article-title>High throughput newborn screening for aromatic <sc>l</sc>&#8208;amino&#8208;acid decarboxylase deficiency by analysis of concentrations of 3&#8208;<italic toggle="yes">O</italic>&#8208;methyldopa from dried blood spots</article-title>. <source>J Inherit Metab Dis</source>. <year>2020</year>;<volume>43</volume>(<issue>3</issue>):<fpage>602</fpage>&#8208;<lpage>610</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12208</pub-id><pub-id pub-id-type="pmid">31849064</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="jimd12697-cit-0135"><string-name name-style="western"><surname>Ginocchio</surname><given-names>VM</given-names></string-name>, <string-name name-style="western"><surname>Ferla</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Auricchio</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brunetti&#8208;Pierri</surname><given-names>N</given-names></string-name>. <article-title>Current status on clinical development of adeno&#8208;associated virus&#8208;mediated liver&#8208;directed gene therapy for inborn errors of metabolism</article-title>. <source>Hum Gene Ther</source>. <year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1204</fpage>&#8208;<lpage>1210</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2019.151</pub-id><pub-id pub-id-type="pmid">31517544</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="jimd12697-cit-0136"><string-name name-style="western"><surname>Massaro</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Geard</surname><given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W</given-names></string-name>, et al. <article-title>Gene therapy for lysosomal storage disorders: ongoing studies and clinical development</article-title>. <source>Biomolecules</source>. <year>2021</year>;<volume>11</volume>(<issue>4</issue>):<elocation-id>611</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/biom11040611</pub-id><pub-id pub-id-type="pmid">33924076</pub-id><pub-id pub-id-type="pmcid">PMC8074255</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="jimd12697-cit-0137"><string-name name-style="western"><surname>Dasgupta</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Flotte</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Keeler</surname><given-names>AM</given-names></string-name>. <article-title>CRISPR/Cas&#8208;dependent and nuclease&#8208;free in vivo therapeutic gene editing</article-title>. <source>Hum Gene Ther</source>. <year>2021</year>;<volume>32</volume>(<issue>5&#8208;6</issue>):<fpage>275</fpage>&#8208;<lpage>293</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2021.013</pub-id><pub-id pub-id-type="pmid">33750221</pub-id><pub-id pub-id-type="pmcid">PMC7987363</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="jimd12697-cit-0138"><string-name name-style="western"><surname>Harmatz</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Prada</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Burton</surname><given-names>BK</given-names></string-name>, et al. <article-title>First&#8208;in&#8208;human in vivo genome editing via AAV&#8208;zinc&#8208;finger nucleases for mucopolysaccharidosis I/II and hemophilia B</article-title>. <source>Mol Ther</source>. <year>2022</year>;<volume>30</volume>(<issue>12</issue>):<fpage>3587</fpage>&#8208;<lpage>3600</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ymthe.2022.10.010</pub-id><pub-id pub-id-type="pmid">36299240</pub-id><pub-id pub-id-type="pmcid">PMC9734078</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="jimd12697-cit-0139"><string-name name-style="western"><surname>Hordeaux</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Buza</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Jeffrey</surname><given-names>B</given-names></string-name>, et al. <article-title>MicroRNA&#8208;mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates</article-title>. <source>Sci Transl Med</source>. <year>2020</year>;<volume>12</volume>(<issue>569</issue>):<elocation-id>eaba9188</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aba9188</pub-id><pub-id pub-id-type="pmid">33177182</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="jimd12697-cit-0140"><string-name name-style="western"><surname>Buss</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lanigan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zeller</surname><given-names>J</given-names></string-name>, et al. <article-title>Characterization of AAV&#8208;mediated dorsal root ganglionopathy</article-title>. <source>Mol Ther Methods Clin Dev</source>. <year>2022</year>;<volume>24</volume>:<fpage>342</fpage>&#8208;<lpage>354</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.omtm.2022.01.013</pub-id><pub-id pub-id-type="pmid">35229008</pub-id><pub-id pub-id-type="pmcid">PMC8851102</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="jimd12697-cit-0141"><string-name name-style="western"><surname>Golebiowski</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>van der Bom</surname><given-names>IMJ</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>C&#8208;S</given-names></string-name>, et al. <article-title>Direct intracranial injection of AAVrh8 encoding monkey &#946;&#8208;N&#8208;acetylhexosaminidase causes neurotoxicity in the primate brain</article-title>. <source>Hum Gene Ther</source>. <year>2017</year>;<volume>28</volume>(<issue>6</issue>):<fpage>510</fpage>&#8208;<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1089/hum.2016.109</pub-id><pub-id pub-id-type="pmid">28132521</pub-id><pub-id pub-id-type="pmcid">PMC5488349</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="jimd12697-cit-0142"><string-name name-style="western"><surname>Strauss</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Farrar</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Muntoni</surname><given-names>F</given-names></string-name>, et al. <article-title>Onasemnogene abeparvovec for presymptomatic infants with two copies of <italic toggle="yes">SMN2</italic> at risk for spinal muscular atrophy type 1: the phase III SPR1NT trial</article-title>. <source>Nat Med</source>. <year>2022</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1381</fpage>&#8208;<lpage>1389</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41591-022-01866-4</pub-id><pub-id pub-id-type="pmid">35715566</pub-id><pub-id pub-id-type="pmcid">PMC9205281</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="jimd12697-cit-0143"><string-name name-style="western"><surname>Chand</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>LaMarca</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Reyna</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Sutter</surname><given-names>T</given-names></string-name>. <article-title>Safety of onasemnogene abeparvovec for patients with spinal muscular atrophy 8.5 kg or heavier in a global managed access program</article-title>. <source>Pediatr Neurol</source>. <year>2022</year>;<volume>132</volume>:<fpage>27</fpage>&#8208;<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2022.05.001</pub-id><pub-id pub-id-type="pmid">35605311</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="jimd12697-cit-0144"><string-name name-style="western"><surname>Day</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Mendell</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Mercuri</surname><given-names>E</given-names></string-name>, et al. <article-title>Clinical trial and postmarketing safety of onasemnogene abeparvovec therapy</article-title>. <source>Drug Saf</source>. <year>2021</year>;<volume>44</volume>(<issue>10</issue>):<fpage>1109</fpage>&#8208;<lpage>1119</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s40264-021-01107-6</pub-id><pub-id pub-id-type="pmid">34383289</pub-id><pub-id pub-id-type="pmcid">PMC8473343</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0145"><label>145</label><mixed-citation publication-type="journal" id="jimd12697-cit-0145"><string-name name-style="western"><surname>Sehara</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Fujimoto</surname><given-names>K&#8208;I</given-names></string-name>, <string-name name-style="western"><surname>Ikeguchi</surname><given-names>K</given-names></string-name>, et al. <article-title>Persistent expression of dopamine&#8208;synthesizing enzymes 15&#8201;years after gene transfer in a primate model of Parkinson's disease</article-title>. <source>Hum Gene Ther Clin Dev</source>. <year>2017</year>;<volume>28</volume>(<issue>2</issue>):<fpage>74</fpage>&#8208;<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1089/humc.2017.010</pub-id><pub-id pub-id-type="pmid">28279081</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0146"><label>146</label><mixed-citation publication-type="journal" id="jimd12697-cit-0146"><string-name name-style="western"><surname>Das</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Vijayan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Walton</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Stafford</surname><given-names>VG</given-names></string-name>, <string-name name-style="western"><surname>Fiflis</surname><given-names>DN</given-names></string-name>, <string-name name-style="western"><surname>Asokan</surname><given-names>A</given-names></string-name>. <article-title>Epigenetic silencing of recombinant adeno&#8208;associated virus genomes by NP220 and the HUSH complex</article-title>. <source>J Virol</source>. <year>2022</year>;<volume>96</volume>(<issue>4</issue>):<elocation-id>e0203921</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/jvi.02039-21</pub-id><pub-id pub-id-type="pmid">34878926</pub-id><pub-id pub-id-type="pmcid">PMC8865469</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0147"><label>147</label><mixed-citation publication-type="journal" id="jimd12697-cit-0147"><string-name name-style="western"><surname>Ojeda</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>&#193;vila</surname><given-names>A</given-names></string-name>. <article-title>Early actions of neurotransmitters during cortex development and maturation of reprogrammed neurons</article-title>. <source>Front Synaptic Neurosci</source>. <year>2019</year>;<volume>11</volume>:<elocation-id>33</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fnsyn.2019.00033</pub-id><pub-id pub-id-type="pmid">31824293</pub-id><pub-id pub-id-type="pmcid">PMC6881277</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0148"><label>148</label><mixed-citation publication-type="journal" id="jimd12697-cit-0148"><string-name name-style="western"><surname>Bozaci</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Er</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yazici</surname><given-names>H</given-names></string-name>, et al. <article-title>Tetrahydrobiopterin deficiencies: lesson from clinical experience</article-title>. <source>JIMD Rep</source>. <year>2021</year>;<volume>59</volume>(<issue>1</issue>):<fpage>42</fpage>&#8208;<lpage>51</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmd2.12199</pub-id><pub-id pub-id-type="pmid">33977029</pub-id><pub-id pub-id-type="pmcid">PMC8100404</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0149"><label>149</label><mixed-citation publication-type="journal" id="jimd12697-cit-0149"><string-name name-style="western"><surname>Trist&#225;n&#8208;Noguero</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>D&#237;ez</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jou</surname><given-names>C</given-names></string-name>, et al. <article-title>Study of a fetal brain affected by a severe form of tyrosine hydroxylase deficiency, a rare cause of early parkinsonism</article-title>. <source>Metab Brain Dis</source>. <year>2016</year>;<volume>31</volume>(<issue>3</issue>):<fpage>705</fpage>&#8208;<lpage>709</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11011-015-9780-z</pub-id><pub-id pub-id-type="pmid">26686676</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0150"><label>150</label><mixed-citation publication-type="journal" id="jimd12697-cit-0150"><string-name name-style="western"><surname>Homma</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sumi&#8208;Ichinose</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Tokuoka</surname><given-names>H</given-names></string-name>, et al. <article-title>Partial biopterin deficiency disturbs postnatal development of the dopaminergic system in the brain</article-title>. <source>J Biol Chem</source>. <year>2011</year>;<volume>286</volume>(<issue>2</issue>):<fpage>1445</fpage>&#8208;<lpage>1452</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M110.159426</pub-id><pub-id pub-id-type="pmid">21062748</pub-id><pub-id pub-id-type="pmcid">PMC3020753</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0151"><label>151</label><mixed-citation publication-type="journal" id="jimd12697-cit-0151"><string-name name-style="western"><surname>Sumi&#8208;Ichinose</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Urano</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Kuroda</surname><given-names>R</given-names></string-name>, et al. <article-title>Catecholamines and serotonin are differently regulated by tetrahydrobiopterin: a study from 6&#8208;pyruvoyltetrahydropterin synthase knockout mice</article-title>. <source>J Biol Chem</source>. <year>2001</year>;<volume>276</volume>(<issue>44</issue>):<fpage>41150</fpage>&#8208;<lpage>41160</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M102237200</pub-id><pub-id pub-id-type="pmid">11517215</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0152"><label>152</label><mixed-citation publication-type="journal" id="jimd12697-cit-0152"><string-name name-style="western"><surname>Jiang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>Y</given-names></string-name>, et al. <article-title>A novel GTPCH deficiency mouse model exhibiting tetrahydrobiopterin&#8208;related metabolic disturbance and infancy&#8208;onset motor impairments</article-title>. <source>Metabolism</source>. <year>2019</year>;<volume>94</volume>:<fpage>96</fpage>&#8208;<lpage>104</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.metabol.2019.02.001</pub-id><pub-id pub-id-type="pmid">30742839</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0153"><label>153</label><mixed-citation publication-type="journal" id="jimd12697-cit-0153"><string-name name-style="western"><surname>Islam</surname><given-names>KUS</given-names></string-name>, <string-name name-style="western"><surname>Meli</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Blaess</surname><given-names>S</given-names></string-name>. <article-title>The development of the mesoprefrontal dopaminergic system in health and disease</article-title>. <source>Front Neural Circuits</source>. <year>2021</year>;<volume>15</volume>:<elocation-id>746582</elocation-id>.<pub-id pub-id-type="pmid">34712123</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fncir.2021.746582</pub-id><pub-id pub-id-type="pmcid">PMC8546303</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0154"><label>154</label><mixed-citation publication-type="journal" id="jimd12697-cit-0154"><string-name name-style="western"><surname>Korner</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Noain</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>M</given-names></string-name>, et al. <article-title>Brain catecholamine depletion and motor impairment in a Th Knock&#8208;in mouse with type B tyrosine hydroxylase deficiency</article-title>. <source>Brain</source>. <year>2015</year>;<volume>138</volume>(<issue>10</issue>):<fpage>2948</fpage>&#8208;<lpage>2963</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awv224</pub-id><pub-id pub-id-type="pmid">26276013</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0155"><label>155</label><mixed-citation publication-type="miscellaneous" id="jimd12697-cit-0155"><collab collab-type="authors">National Institute for Health and Care Excellence</collab>
. <article-title>Eladocagene Exuparvovec for Treating Aromatic <sc>l</sc>&#8208;Amino Acid Decarboxylase Deficiency</article-title>. Accessed May 23, 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/hst26/chapter/2-Information-about-eladocagene-exuparvovec" ext-link-type="uri">https://www.nice.org.uk/guidance/hst26/chapter/2-Information-about-eladocagene-exuparvovec</ext-link></mixed-citation></ref><ref id="jimd12697-bib-0156"><label>156</label><mixed-citation publication-type="journal" id="jimd12697-cit-0156"><string-name name-style="western"><surname>J&#248;rgensen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kefalas</surname><given-names>P</given-names></string-name>. <article-title>The use of innovative payment mechanisms for gene therapies in Europe and the USA</article-title>. <source>Regen Med</source>. <year>2021</year>;<volume>16</volume>(<issue>4</issue>):<fpage>405</fpage>&#8208;<lpage>422</lpage>. doi:<pub-id pub-id-type="doi">10.2217/rme-2020-0169</pub-id><pub-id pub-id-type="pmid">33847163</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0157"><label>157</label><mixed-citation publication-type="journal" id="jimd12697-cit-0157"><string-name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mallela</surname><given-names>KMG</given-names></string-name>, <string-name name-style="western"><surname>Deorkar</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brophy</surname><given-names>G</given-names></string-name>. <article-title>Manufacturing challenges and rational formulation development for AAV viral vectors</article-title>. <source>J Pharm Sci</source>. <year>2021</year>;<volume>110</volume>(<issue>7</issue>):<fpage>2609</fpage>&#8208;<lpage>2624</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.xphs.2021.03.024</pub-id><pub-id pub-id-type="pmid">33812887</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0158"><label>158</label><mixed-citation publication-type="journal" id="jimd12697-cit-0158"><string-name name-style="western"><surname>Green</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Samaranch</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>HS</given-names></string-name>, et al. <article-title>Axonal transport of AAV9 in nonhuman primate brain</article-title>. <source>Gene Ther</source>. <year>2016</year>;<volume>23</volume>(<issue>6</issue>):<fpage>520</fpage>&#8208;<lpage>526</lpage>. doi:<pub-id pub-id-type="doi">10.1038/gt.2016.24</pub-id><pub-id pub-id-type="pmid">26953486</pub-id><pub-id pub-id-type="pmcid">PMC4893316</pub-id></mixed-citation></ref><ref id="jimd12697-bib-0159"><label>159</label><mixed-citation publication-type="journal" id="jimd12697-cit-0159"><string-name name-style="western"><surname>Roubertie</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Opladen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Brennenstuhl</surname><given-names>H</given-names></string-name>, et al. <article-title>Gene therapy for aromatic <sc>l</sc>&#8208;amino acid decarboxylase deficiency: requirements for safe application and knowledge&#8208;generating follow&#8208;up</article-title>. <source>J Inherit Metab Dis</source>. <year>2023</year>;<fpage>1</fpage>&#8208;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jimd.12649</pub-id><pub-id pub-id-type="pmid">37402126</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>